

COVID-19 Correlates of Risk Analysis Report
MockCOVE Study

USG COVID-19 Response Biostatistics Team

June 17, 2021

Contents

| | | |
|----------|--|------------|
| 1 | Disclaimers | 29 |
| 2 | Summary Tables | 31 |
| 2.1 | Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Negative Per-Protocol Cohort | 31 |
| 2.2 | Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Positive Per-Protocol Cohort | 33 |
| 2.3 | Sample Sizes of Baseline Strata for Correlates of Risk Analysis | 34 |
| 2.4 | Antibody levels in the baseline SARS-CoV-2 negative per-protocol cohort (vaccine recipients) | 35 |
| 2.5 | Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (vaccine recipients) | 37 |
| 2.6 | Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (placebo recipients) | 39 |
| 3 | Graphical Descriptions of Antibody Marker Data | 41 |
| 3.1 | Boxplots | 42 |
| 3.2 | Weighted RCDF plots | 46 |
| 3.3 | Weighted RCDF plots of threshold correlate concentration for vaccine efficacy | 50 |
| 3.4 | Spaghetti plots | 54 |
| 3.5 | Violin and line plots | 55 |
| 4 | Day 57 Univariate CoR: Cox Models of Risk | 327 |
| 4.1 | Hazard ratios | 327 |
| 4.2 | Marginalized risk and controlled vaccine efficacy plots | 332 |
| 5 | Day 29 Univariate CoR: Cox Models of Risk | 337 |
| 5.1 | Hazard ratios | 337 |
| 5.2 | Marginalized risk and controlled vaccine efficacy plots | 342 |
| 6 | Univariate CoR: Nonparametric Threshold Modeling (>=s) | 347 |
| 6.1 | Plots and Tables with estimates and pointwise confidence interval for Day 57 | 348 |
| 6.2 | Plots and Tables with estimates and pointwise confidence intervals for Day 29 | 353 |

| | | |
|-----------|--|------------|
| 6.3 | Plots and Tables with estimates and pointwise confidence interval for Day 57 (monotone-corrected) | 358 |
| 6.4 | Plots and Tables with estimates and pointwise confidence intervals for Day 29 (monotone-corrected) | 363 |
| 6.5 | Plots and Tables with estimates and simultaneous confidence bands for Day 57 | 368 |
| 6.6 | Plots and Tables with estimates and simultaneous confidence bands for Day 29 | 373 |
| 6.7 | Plots and Tables with estimates and pointwise confidence interval for Day 57 (monotone-corrected) | 378 |
| 6.8 | Plots and Tables with estimates and pointwise confidence intervals for Day 29 (monotone-corrected) | 383 |
| 7 | Univariate CoR: Nonparametric Threshold Modeling (<=s) | 389 |
| 7.1 | Plots and Tables with estimates and pointwise confidence interval for Day 57 | 389 |
| 7.2 | Plots and Tables with estimates and pointwise confidence intervals for Day 29 | 394 |
| 7.3 | Plots and Tables with estimates and pointwise confidence interval for Day 57 (monotone-corrected) | 399 |
| 7.4 | Plots and Tables with estimates and pointwise confidence intervals for Day 29 (monotone-corrected) | 404 |
| 7.5 | Plots and Tables with estimates and simultaneous confidence bands for Day 57 | 409 |
| 7.6 | Plots and Tables with estimates and simultaneous confidence bands for Day 29 | 414 |
| 7.7 | Plots and Tables with estimates and pointwise confidence interval for Day 57 (monotone-corrected) | 419 |
| 7.8 | Plots and Tables with estimates and pointwise confidence intervals for Day 29 (monotone-corrected) | 424 |
| 8 | Day 57 Univariate CoR: Nonlinear modeling | 429 |
| 9 | Day 29 Univariate CoR: Nonlinear modeling | 433 |
| 10 | Appendix | 437 |

List of Tables

| | | |
|-----|---|-----|
| 2.1 | Table 1. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Negative Per-Protocol Cohort | 31 |
| 2.2 | Table 2. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Positive Per-Protocol Cohort | 33 |
| 2.3 | Table 3. Sample Sizes of Baseline Strata for Correlates of Risk Analysis | 34 |
| 2.4 | Table 4. Antibody levels in the baseline SARS-CoV-2 negative per-protocol cohort (vaccine recipients) | 35 |
| 2.5 | Table 5. Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (vaccine recipients) | 37 |
| 2.6 | Table 6. Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (placebo recipients) | 39 |
| 4.1 | Inference for Day 57 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios per 10-fold increment in the marker* | 327 |
| 4.2 | Inference for Day 57 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios for Middle vs. Upper tertile vs. Lower tertile* | 328 |
| 5.1 | Inference for Day 29 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios per 10-fold increment in the marker* | 337 |
| 5.2 | Inference for Day 29 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios for Middle vs. Upper tertile vs. Lower tertile* | 338 |
| 6.1 | Table of risk estimates for a range of thresholds of Day 57 Spike protein binding antibody levels with pointwise 95% confidence intervals. | 349 |
| 6.2 | Table of risk estimates for a range of thresholds of Day 57 RBD binding antibody levels with pointwise 95% confidence intervals. | 350 |
| 6.3 | Table of risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals. | 351 |
| 6.4 | Table of risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals. | 352 |
| 6.5 | Table of risk estimates for a range of thresholds of Day 29 Spike protein antibody levels with pointwise 95% confidence intervals. | 354 |
| 6.6 | Table of risk estimates for a range of thresholds of Day 29 RBD binding antibody levels with pointwise 95% confidence intervals. | 355 |

| | | |
|------|--|-----|
| 6.7 | Table of risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals. | 356 |
| 6.8 | Table of risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals. | 357 |
| 6.9 | Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Spike protein binding antibody levels with pointwise 95% confidence intervals. | 359 |
| 6.10 | Table of monotone-corrected risk estimates for a range of thresholds of Day 57 RBD binding antibody levels with pointwise 95% confidence intervals. | 360 |
| 6.11 | Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals. | 361 |
| 6.12 | Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals. | 362 |
| 6.13 | Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Spike protein antibody levels with pointwise 95% confidence intervals. | 364 |
| 6.14 | Table of monotone-corrected risk estimates for a range of thresholds of Day 29 RBD binding antibody levels with pointwise 95% confidence intervals. | 365 |
| 6.15 | Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals. | 366 |
| 6.16 | Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals. | 367 |
| 6.17 | Table of risk estimates for a range of thresholds of Day 57 Spike protein binding antibody levels with simultaneous 95% confidence intervals. | 369 |
| 6.18 | Table of risk estimates for a range of thresholds of Day 57 RBD binding antibody levels with simultaneous 95% confidence intervals. | 370 |
| 6.19 | Table of risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals. | 371 |
| 6.20 | Table of risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals. | 372 |
| 6.21 | Table of risk estimates for a range of thresholds of Day 29 Spike protein antibody levels with simultaneous 95% confidence intervals. | 374 |
| 6.22 | Table of risk estimates for a range of thresholds of Day 29 RBD binding antibody levels with simultaneous 95% confidence intervals. | 375 |
| 6.23 | Table of risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals. | 376 |
| 6.24 | Table of risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals. | 377 |
| 6.25 | Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Spike protein binding antibody levels with simultaneous 95% confidence intervals. | 379 |
| 6.26 | Table of monotone-corrected risk estimates for a range of thresholds of Day 57 RBD binding antibody levels with simultaneous 95% confidence intervals. | 380 |
| 6.27 | Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals. | 381 |
| 6.28 | Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals. | 382 |

| | | |
|------|--|-----|
| 6.29 | Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Spike protein antibody levels with simultaneous 95% confidence intervals. | 384 |
| 6.30 | Table of monotone-corrected risk estimates for a range of thresholds of Day 29 RBD binding antibody levels with simultaneous 95% confidence intervals. | 385 |
| 6.31 | Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals. | 386 |
| 6.32 | Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals. | 387 |
| 7.1 | Table of risk estimates for a range of thresholds of Day 57 Spike protein binding antibody levels with pointwise 95% confidence intervals. | 390 |
| 7.2 | Table of risk estimates for a range of thresholds of Day 57 RBD binding antibody levels with pointwise 95% confidence intervals. | 391 |
| 7.3 | Table of risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals. | 392 |
| 7.4 | Table of risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals. | 393 |
| 7.5 | Table of risk estimates for a range of thresholds of Day 29 Spike protein antibody levels with pointwise 95% confidence intervals. | 395 |
| 7.6 | Table of risk estimates for a range of thresholds of Day 29 RBD binding antibody levels with pointwise 95% confidence intervals. | 396 |
| 7.7 | Table of risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals. | 397 |
| 7.8 | Table of risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals. | 398 |
| 7.9 | Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Spike protein binding antibody levels with pointwise 95% confidence intervals. | 400 |
| 7.10 | Table of monotone-corrected risk estimates for a range of thresholds of Day 57 RBD binding antibody levels with pointwise 95% confidence intervals. | 401 |
| 7.11 | Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals. | 402 |
| 7.12 | Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals. | 403 |
| 7.13 | Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Spike protein antibody levels with pointwise 95% confidence intervals. | 405 |
| 7.14 | Table of monotone-corrected risk estimates for a range of thresholds of Day 29 RBD binding antibody levels with pointwise 95% confidence intervals. | 406 |
| 7.15 | Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals. | 407 |
| 7.16 | Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals. | 408 |
| 7.17 | Table of risk estimates for a range of thresholds of Day 57 Spike protein binding antibody levels with simultaneous 95% confidence intervals. | 410 |

| | |
|---|-----|
| 7.18 Table of risk estimates for a range of thresholds of Day 57 RBD binding antibody levels with simultaneous 95% confidence intervals. | 411 |
| 7.19 Table of risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals. | 412 |
| 7.20 Table of risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals. | 413 |
| 7.21 Table of risk estimates for a range of thresholds of Day 29 Spike protein antibody levels with simultaneous 95% confidence intervals. | 415 |
| 7.22 Table of risk estimates for a range of thresholds of Day 29 RBD binding antibody levels with simultaneous 95% confidence intervals. | 416 |
| 7.23 Table of risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals. | 417 |
| 7.24 Table of risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals. | 418 |
| 7.25 Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Spike protein binding antibody levels with simultaneous 95% confidence intervals. | 420 |
| 7.26 Table of monotone-corrected risk estimates for a range of thresholds of Day 57 RBD binding antibody levels with simultaneous 95% confidence intervals. | 421 |
| 7.27 Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals. | 422 |
| 7.28 Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals. | 423 |
| 7.29 Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Spike protein antibody levels with simultaneous 95% confidence intervals. | 425 |
| 7.30 Table of monotone-corrected risk estimates for a range of thresholds of Day 29 RBD binding antibody levels with simultaneous 95% confidence intervals. | 426 |
| 7.31 Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals. | 427 |
| 7.32 Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals. | 428 |

List of Figures

| | | |
|------|---|----|
| 3.1 | Boxplots of D57 Ab markers: vaccine arm. The three dashed lines in each figure are ULOQ, LLOQ, and LLOD, from top to bottom respectively. | 42 |
| 3.2 | Boxplots of D57 fold-rise over D1 Ab markers: vaccine arm. | 43 |
| 3.3 | Boxplots of D29 Ab markers: vaccine arm. The three dashed lines in each figure are ULOQ, LLOQ, and LLOD, from top to bottom respectively. | 44 |
| 3.4 | Boxplots of D29 fold-rise over D1 Ab markers: vaccine arm. | 45 |
| 3.5 | RCDF plots for D57 Ab markers by treatment arm. | 46 |
| 3.6 | RCDF plots for D57 fold-rise over D1 Ab markers by treatment arm. | 47 |
| 3.7 | RCDF plots for D29 Ab markers by treatment arm. | 48 |
| 3.8 | RCDF plots for D29 fold-rise over D1 Ab markers by treatment arm. | 49 |
| 3.9 | Marker RCDF of D57 anti-Spike binding Ab: vaccine arm | 50 |
| 3.10 | Marker RCDF of D57 anti-RBD binding Ab: vaccine arm | 51 |
| 3.11 | Marker RCDF of D57 PsV-nAb ID50: vaccine arm | 52 |
| 3.12 | Marker RCDF of D57 PsV-nAb ID80: vaccine arm | 53 |
| 3.13 | Spaghetti Plots of Marker Trajectory: vaccine arm | 54 |
| 3.14 | lineplots of Binding Antibody to Spike: baseline negative placebo arm (version 1) | 55 |
| 3.15 | lineplots of Binding Antibody to Spike: baseline negative vaccine arm (version 1) | 56 |
| 3.16 | lineplots of Binding Antibody to RBD: baseline negative placebo arm (version 1) | 57 |
| 3.17 | lineplots of Binding Antibody to RBD: baseline negative vaccine arm (version 1) | 58 |
| 3.18 | lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm (version 1) | 59 |
| 3.19 | lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm (version 1) | 60 |
| 3.20 | lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm (version 1) | 61 |
| 3.21 | lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm (version 1) | 62 |
| 3.22 | violinplots of Binding Antibody to Spike: baseline negative placebo arm (version 1) | 63 |
| 3.23 | violinplots of Binding Antibody to Spike: baseline negative vaccine arm (version 1) | 64 |
| 3.24 | violinplots of Binding Antibody to RBD: baseline negative placebo arm (version 1) | 65 |
| 3.25 | violinplots of Binding Antibody to RBD: baseline negative vaccine arm (version 1) | 66 |
| 3.26 | violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm (version 1) | 67 |
| 3.27 | violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm (version 1) | 68 |

| | |
|---|-----|
| 3.28 violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm (version 1) | 69 |
| 3.29 violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm (version 1) | 70 |
| 3.30 lineplots of Binding Antibody to Spike: baseline negative placebo arm (version 2) | 71 |
| 3.31 lineplots of Binding Antibody to Spike: baseline negative vaccine arm (version 2) | 72 |
| 3.32 lineplots of Binding Antibody to RBD: baseline negative placebo arm (version 2) | 73 |
| 3.33 lineplots of Binding Antibody to RBD: baseline negative vaccine arm (version 2) | 74 |
| 3.34 lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm (version 2) | 75 |
| 3.35 lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm (version 2) | 76 |
| 3.36 lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm (version 2) | 77 |
| 3.37 lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm (version 2) | 78 |
| 3.38 violinplots of Binding Antibody to Spike: baseline negative placebo arm (version 2) | 79 |
| 3.39 violinplots of Binding Antibody to Spike: baseline negative vaccine arm (version 2) | 80 |
| 3.40 violinplots of Binding Antibody to RBD: baseline negative placebo arm (version 2) | 81 |
| 3.41 violinplots of Binding Antibody to RBD: baseline negative vaccine arm (version 2) | 82 |
| 3.42 violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm (version 2) | 83 |
| 3.43 violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm (version 2) | 84 |
| 3.44 violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm (version 2) | 85 |
| 3.45 violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm (version 2) | 86 |
| 3.46 lineplots of Binding Antibody to Spike: baseline negative placebo arm by age (version 1) | 87 |
| 3.47 lineplots of Binding Antibody to Spike: baseline negative vaccine arm by age (version 1) | 88 |
| 3.48 lineplots of Binding Antibody to RBD: baseline negative placebo arm by age (version 1) | 89 |
| 3.49 lineplots of Binding Antibody to RBD: baseline negative vaccine arm by age (version 1) | 90 |
| 3.50 lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age (version 1) | 91 |
| 3.51 lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age (version 1) | 92 |
| 3.52 lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age (version 1) | 93 |
| 3.53 lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age (version 1) | 94 |
| 3.54 violinplots of Binding Antibody to Spike: baseline negative placebo arm by age (version 1) | 95 |
| 3.55 violinplots of Binding Antibody to Spike: baseline negative vaccine arm by age (version 1) | 96 |
| 3.56 violinplots of Binding Antibody to RBD: baseline negative placebo arm by age (version 1) | 97 |
| 3.57 violinplots of Binding Antibody to RBD: baseline negative vaccine arm by age (version 1) | 98 |
| 3.58 violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age (version 1) | 99 |
| 3.59 violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age (version 1) | 100 |
| 3.60 violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age (version 1) | 101 |
| 3.61 violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age (version 1) | 102 |

| | |
|--|-----|
| 3.62 lineplots of Binding Antibody to Spike: baseline negative placebo arm by age (version 2) | 103 |
| 3.63 lineplots of Binding Antibody to Spike: baseline negative vaccine arm by age (version 2) | 104 |
| 3.64 lineplots of Binding Antibody to RBD: baseline negative placebo arm by age (version 2) | 105 |
| 3.65 lineplots of Binding Antibody to RBD: baseline negative vaccine arm by age (version 2) | 106 |
| 3.66 lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age (version 2) | 107 |
| 3.67 lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age (version 2) | 108 |
| 3.68 lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age (version 2) | 109 |
| 3.69 lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age (version 2) | 110 |
| 3.70 violinplots of Binding Antibody to Spike: baseline negative placebo arm by age (version 2) | 111 |
| 3.71 violinplots of Binding Antibody to Spike: baseline negative vaccine arm by age (version 2) | 112 |
| 3.72 violinplots of Binding Antibody to RBD: baseline negative placebo arm by age (version 2) | 113 |
| 3.73 violinplots of Binding Antibody to RBD: baseline negative vaccine arm by age (version 2) | 114 |
| 3.74 violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age (version 2) | 115 |
| 3.75 violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age (version 2) | 116 |
| 3.76 violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age (version 2) | 117 |
| 3.77 violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age (version 2) | 118 |
| 3.78 lineplots of Binding Antibody to Spike: baseline negative placebo arm by risk condition (version 1) | 119 |
| 3.79 lineplots of Binding Antibody to Spike: baseline negative vaccine arm by risk condition (version 1) | 120 |
| 3.80 lineplots of Binding Antibody to RBD: baseline negative placebo arm by risk condition (version 1) | 121 |
| 3.81 lineplots of Binding Antibody to RBD: baseline negative vaccine arm by risk condition (version 1) | 122 |
| 3.82 lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by risk condition (version 1) | 123 |
| 3.83 lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by risk condition (version 1) | 124 |
| 3.84 lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by risk condition (version 1) | 125 |
| 3.85 lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by risk condition (version 1) | 126 |
| 3.86 violinplots of Binding Antibody to Spike: baseline negative placebo arm by risk condition (version 1) | 127 |
| 3.87 violinplots of Binding Antibody to Spike: baseline negative vaccine arm by risk condition (version 1) | 128 |
| 3.88 violinplots of Binding Antibody to RBD: baseline negative placebo arm by risk condition (version 1) | 129 |

| | |
|---|-----|
| 3.89 violinplots of Binding Antibody to RBD: baseline negative vaccine arm by risk condition (version 1) | 130 |
| 3.90 violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by risk condition (version 1) | 131 |
| 3.91 violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by risk condition (version 1) | 132 |
| 3.92 violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by risk condition (version 1) | 133 |
| 3.93 violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by risk condition (version 1) | 134 |
| 3.94 lineplots of Binding Antibody to Spike: baseline negative placebo arm by risk condition (version 2) | 135 |
| 3.95 lineplots of Binding Antibody to Spike: baseline negative vaccine arm by risk condition (version 2) | 136 |
| 3.96 lineplots of Binding Antibody to RBD: baseline negative placebo arm by risk condition (version 2) | 137 |
| 3.97 lineplots of Binding Antibody to RBD: baseline negative vaccine arm by risk condition (version 2) | 138 |
| 3.98 lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by risk condition (version 2) | 139 |
| 3.99 lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by risk condition (version 2) | 140 |
| 3.100 lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by risk condition (version 2) | 141 |
| 3.101 lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by risk condition (version 2) | 142 |
| 3.102 violinplots of Binding Antibody to Spike: baseline negative placebo arm by risk condition (version 2) | 143 |
| 3.103 violinplots of Binding Antibody to Spike: baseline negative vaccine arm by risk condition (version 2) | 144 |
| 3.104 violinplots of Binding Antibody to RBD: baseline negative placebo arm by risk condition (version 2) | 145 |
| 3.105 violinplots of Binding Antibody to RBD: baseline negative vaccine arm by risk condition (version 2) | 146 |
| 3.106 violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by risk condition (version 2) | 147 |
| 3.107 violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by risk condition (version 2) | 148 |
| 3.108 violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by risk condition (version 2) | 149 |
| 3.109 violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by risk condition (version 2) | 150 |
| 3.110 lineplots of Binding Antibody to Spike: baseline negative placebo arm by age and risk condition (version 1) | 151 |

| | |
|---|-----|
| 3.111lineplots of Binding Antibody to Spike: baseline negative vaccine arm by age and risk condition (version 1) | 152 |
| 3.112lineplots of Binding Antibody to RBD: baseline negative placebo arm by age and risk condition (version 1) | 153 |
| 3.113lineplots of Binding Antibody to RBD: baseline negative vaccine arm by age and risk condition (version 1) | 154 |
| 3.114lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age and risk condition (version 1) | 155 |
| 3.115lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age and risk condition (version 1) | 156 |
| 3.116lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age and risk condition (version 1) | 157 |
| 3.117lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age and risk condition (version 1) | 158 |
| 3.118violinplots of Binding Antibody to Spike: baseline negative placebo arm by age and risk condition (version 1) | 159 |
| 3.119violinplots of Binding Antibody to Spike: baseline negative vaccine arm by age and risk condition (version 1) | 160 |
| 3.120violinplots of Binding Antibody to RBD: baseline negative placebo arm by age and risk con- dition (version 1) | 161 |
| 3.121violinplots of Binding Antibody to RBD: baseline negative vaccine arm by age and risk con- dition (version 1) | 162 |
| 3.122violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age and risk condition (version 1) | 163 |
| 3.123violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age and risk condition (version 1) | 164 |
| 3.124violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age and risk condition (version 1) | 165 |
| 3.125violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age and risk condition (version 1) | 166 |
| 3.126lineplots of Binding Antibody to Spike: baseline negative placebo arm by age and risk condi- tion (version 2) | 167 |
| 3.127lineplots of Binding Antibody to Spike: baseline negative vaccine arm by age and risk condition (version 2) | 168 |
| 3.128lineplots of Binding Antibody to RBD: baseline negative placebo arm by age and risk condition (version 2) | 169 |
| 3.129lineplots of Binding Antibody to RBD: baseline negative vaccine arm by age and risk condition (version 2) | 170 |
| 3.130lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age and risk condition (version 2) | 171 |
| 3.131lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age and risk condition (version 2) | 172 |
| 3.132lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age and risk condition (version 2) | 173 |

| | |
|--|-----|
| 3.133lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age and risk condition (version 2) | 174 |
| 3.134violinplots of Binding Antibody to Spike: baseline negative placebo arm by age and risk condition (version 2) | 175 |
| 3.135violinplots of Binding Antibody to Spike: baseline negative vaccine arm by age and risk condition (version 2) | 176 |
| 3.136violinplots of Binding Antibody to RBD: baseline negative placebo arm by age and risk condition (version 2) | 177 |
| 3.137violinplots of Binding Antibody to RBD: baseline negative vaccine arm by age and risk condition (version 2) | 178 |
| 3.138violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age and risk condition (version 2) | 179 |
| 3.139violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age and risk condition (version 2) | 180 |
| 3.140violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age and risk condition (version 2) | 181 |
| 3.141violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age and risk condition (version 2) | 182 |
| 3.142lineplots of Binding Antibody to Spike: baseline negative placebo arm by sex assigned at birth (version 1) | 183 |
| 3.143lineplots of Binding Antibody to Spike: baseline negative vaccine arm by sex assigned at birth (version 1) | 184 |
| 3.144lineplots of Binding Antibody to RBD: baseline negative placebo arm by sex assigned at birth (version 1) | 185 |
| 3.145lineplots of Binding Antibody to RBD: baseline negative vaccine arm by sex assigned at birth (version 1) | 186 |
| 3.146lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by sex assigned at birth (version 1) | 187 |
| 3.147lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by sex assigned at birth (version 1) | 188 |
| 3.148lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by sex assigned at birth (version 1) | 189 |
| 3.149lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by sex assigned at birth (version 1) | 190 |
| 3.150violinplots of Binding Antibody to Spike: baseline negative placebo arm by sex assigned at birth (version 1) | 191 |
| 3.151violinplots of Binding Antibody to Spike: baseline negative vaccine arm by sex assigned at birth (version 1) | 192 |
| 3.152violinplots of Binding Antibody to RBD: baseline negative placebo arm by sex assigned at birth (version 1) | 193 |
| 3.153violinplots of Binding Antibody to RBD: baseline negative vaccine arm by sex assigned at birth (version 1) | 194 |
| 3.154violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by sex assigned at birth (version 1) | 195 |

| | |
|---|-----|
| 3.155violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by sex assigned at birth (version 1) | 196 |
| 3.156violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by sex assigned at birth (version 1) | 197 |
| 3.157violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by sex assigned at birth (version 1) | 198 |
| 3.158lineplots of Binding Antibody to Spike: baseline negative placebo arm by sex assigned at birth (version 2) | 199 |
| 3.159lineplots of Binding Antibody to Spike: baseline negative vaccine arm by sex assigned at birth (version 2) | 200 |
| 3.160lineplots of Binding Antibody to RBD: baseline negative placebo arm by sex assigned at birth (version 2) | 201 |
| 3.161lineplots of Binding Antibody to RBD: baseline negative vaccine arm by sex assigned at birth (version 2) | 202 |
| 3.162lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by sex assigned at birth (version 2) | 203 |
| 3.163lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by sex assigned at birth (version 2) | 204 |
| 3.164lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by sex assigned at birth (version 2) | 205 |
| 3.165lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by sex assigned at birth (version 2) | 206 |
| 3.166violinplots of Binding Antibody to Spike: baseline negative placebo arm by sex assigned at birth (version 2) | 207 |
| 3.167violinplots of Binding Antibody to Spike: baseline negative vaccine arm by sex assigned at birth (version 2) | 208 |
| 3.168violinplots of Binding Antibody to RBD: baseline negative placebo arm by sex assigned at birth (version 2) | 209 |
| 3.169violinplots of Binding Antibody to RBD: baseline negative vaccine arm by sex assigned at birth (version 2) | 210 |
| 3.170violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by sex assigned at birth (version 2) | 211 |
| 3.171violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by sex assigned at birth (version 2) | 212 |
| 3.172violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by sex assigned at birth (version 2) | 213 |
| 3.173violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by sex assigned at birth (version 2) | 214 |
| 3.174lineplots of Binding Antibody to Spike: baseline negative placebo arm by race and ethnic group (version 1) | 215 |
| 3.175lineplots of Binding Antibody to Spike: baseline negative vaccine arm by race and ethnic group (version 1) | 216 |
| 3.176lineplots of Binding Antibody to RBD: baseline negative placebo arm by race and ethnic group (version 1) | 217 |

| | |
|---|-----|
| 3.177lineplots of Binding Antibody to RBD: baseline negative vaccine arm by race and ethnic group (version 1) | 218 |
| 3.178lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by race and ethnic group (version 1) | 219 |
| 3.179lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by race and ethnic group (version 1) | 220 |
| 3.180lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by race and ethnic group (version 1) | 221 |
| 3.181lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by race and ethnic group (version 1) | 222 |
| 3.182violinplots of Binding Antibody to Spike: baseline negative placebo arm by race and ethnic group (version 1) | 223 |
| 3.183violinplots of Binding Antibody to Spike: baseline negative vaccine arm by race and ethnic group (version 1) | 224 |
| 3.184violinplots of Binding Antibody to RBD: baseline negative placebo arm by race and ethnic group (version 1) | 225 |
| 3.185violinplots of Binding Antibody to RBD: baseline negative vaccine arm by race and ethnic group (version 1) | 226 |
| 3.186violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by race and ethnic group (version 1) | 227 |
| 3.187violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by race and ethnic group (version 1) | 228 |
| 3.188violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by race and ethnic group (version 1) | 229 |
| 3.189violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by race and ethnic group (version 1) | 230 |
| 3.190lineplots of Binding Antibody to Spike: baseline negative placebo arm by race and ethnic group (version 2) | 231 |
| 3.191lineplots of Binding Antibody to Spike: baseline negative vaccine arm by race and ethnic group (version 2) | 232 |
| 3.192lineplots of Binding Antibody to RBD: baseline negative placebo arm by race and ethnic group (version 2) | 233 |
| 3.193lineplots of Binding Antibody to RBD: baseline negative vaccine arm by race and ethnic group (version 2) | 234 |
| 3.194lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by race and ethnic group (version 2) | 235 |
| 3.195lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by race and ethnic group (version 2) | 236 |
| 3.196lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by race and ethnic group (version 2) | 237 |
| 3.197lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by race and ethnic group (version 2) | 238 |
| 3.198violinplots of Binding Antibody to Spike: baseline negative placebo arm by race and ethnic group (version 2) | 239 |

| | |
|---|-----|
| 3.199violinplots of Binding Antibody to Spike: baseline negative vaccine arm by race and ethnic group (version 2) | 240 |
| 3.200violinplots of Binding Antibody to RBD: baseline negative placebo arm by race and ethnic group (version 2) | 241 |
| 3.201violinplots of Binding Antibody to RBD: baseline negative vaccine arm by race and ethnic group (version 2) | 242 |
| 3.202violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by race and ethnic group (version 2) | 243 |
| 3.203violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by race and ethnic group (version 2) | 244 |
| 3.204violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by race and ethnic group (version 2) | 245 |
| 3.205violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by race and ethnic group (version 2) | 246 |
| 3.206lineplots of Binding Antibody to Spike: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1) | 247 |
| 3.207lineplots of Binding Antibody to Spike: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1) | 248 |
| 3.208lineplots of Binding Antibody to RBD: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1) | 249 |
| 3.209lineplots of Binding Antibody to RBD: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1) | 250 |
| 3.210lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1) | 251 |
| 3.211lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1) | 252 |
| 3.212lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1) | 253 |
| 3.213lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1) | 254 |
| 3.214violinplots of Binding Antibody to Spike: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1) | 255 |
| 3.215violinplots of Binding Antibody to Spike: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1) | 256 |
| 3.216violinplots of Binding Antibody to RBD: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1) | 257 |
| 3.217violinplots of Binding Antibody to RBD: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1) | 258 |
| 3.218violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1) | 259 |
| 3.219violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1) | 260 |
| 3.220violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1) | 261 |

| | |
|---|-----|
| 3.221violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1) | 262 |
| 3.222lineplots of Binding Antibody to Spike: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2) | 263 |
| 3.223lineplots of Binding Antibody to Spike: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2) | 264 |
| 3.224lineplots of Binding Antibody to RBD: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2) | 265 |
| 3.225lineplots of Binding Antibody to RBD: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2) | 266 |
| 3.226lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2) | 267 |
| 3.227lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2) | 268 |
| 3.228lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2) | 269 |
| 3.229lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2) | 270 |
| 3.230violinplots of Binding Antibody to Spike: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2) | 271 |
| 3.231violinplots of Binding Antibody to Spike: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2) | 272 |
| 3.232violinplots of Binding Antibody to RBD: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2) | 273 |
| 3.233violinplots of Binding Antibody to RBD: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2) | 274 |
| 3.234violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2) | 275 |
| 3.235violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2) | 276 |
| 3.236violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2) | 277 |
| 3.237violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2) | 278 |
| 3.238scatterplots of Binding Antibody to Spike vs Age: baseline negative vaccine arm at day 1 . . | 279 |
| 3.239scatterplots of Binding Antibody to Spike vs Age: baseline negative vaccine arm at day 29 . | 280 |
| 3.240scatterplots of Binding Antibody to Spike vs Age: baseline negative vaccine arm at day 57 . | 281 |
| 3.241scatterplots of Binding Antibody to RBD vs Age: baseline negative vaccine arm at day 1 . . | 282 |
| 3.242scatterplots of Binding Antibody to RBD vs Age: baseline negative vaccine arm at day 29 . | 283 |
| 3.243scatterplots of Binding Antibody to RBD vs Age: baseline negative vaccine arm at day 57 . | 284 |
| 3.244scatterplots of Pseudovirus Neutralization ID50 vs Age: baseline negative vaccine arm at day 1 | 285 |
| 3.245scatterplots of Pseudovirus Neutralization ID50 vs Age: baseline negative vaccine arm at day 29 . | 286 |

| | |
|--|-----|
| 3.246scatterplots of Pseudovirus Neutralization ID50 vs Age: baseline negative vaccine arm at day 57 | 287 |
| 3.247scatterplots of Pseudovirus Neutralization ID80 vs Age: baseline negative vaccine arm at day 1 | 288 |
| 3.248scatterplots of Pseudovirus Neutralization ID80 vs Age: baseline negative vaccine arm at day 29 | 289 |
| 3.249scatterplots of Pseudovirus Neutralization ID80 vs Age: baseline negative vaccine arm at day 57 | 290 |
| 3.250scatterplots of Binding Antibody to Spike vs Age: by arm at day 1 | 291 |
| 3.251scatterplots of Binding Antibody to Spike vs Age: by arm at day 29 | 292 |
| 3.252scatterplots of Binding Antibody to Spike vs Age: by arm at day 57 | 293 |
| 3.253scatterplots of Binding Antibody to RBD vs Age: by arm at day 1 | 294 |
| 3.254scatterplots of Binding Antibody to RBD vs Age: by arm at day 29 | 295 |
| 3.255scatterplots of Binding Antibody to RBD vs Age: by arm at day 57 | 296 |
| 3.256scatterplots of Pseudovirus Neutralization ID50 vs Age vs Age: by arm at day 1 | 297 |
| 3.257scatterplots of Pseudovirus Neutralization ID50 vs Age vs Age: by arm at day 29 | 298 |
| 3.258scatterplots of Pseudovirus Neutralization ID50 vs Age: by arm at day 57 | 299 |
| 3.259scatterplots of Pseudovirus Neutralization ID80 vs Age: by arm at day 1 | 300 |
| 3.260scatterplots of Pseudovirus Neutralization ID80 vs Age: by arm at day 29 | 301 |
| 3.261scatterplots of Pseudovirus Neutralization ID80 vs Age: by arm at day 57 | 302 |
| 3.262scatterplots of Binding Antibody to Spike vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 1 | 303 |
| 3.263scatterplots of Binding Antibody to Spike vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 29 | 304 |
| 3.264scatterplots of Binding Antibody to Spike vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 57 | 305 |
| 3.265scatterplots of Binding Antibody to RBD vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 1 | 306 |
| 3.266scatterplots of Binding Antibody to RBD vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 29 | 307 |
| 3.267scatterplots of Binding Antibody to RBD vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 57 | 308 |
| 3.268scatterplots of Pseudovirus Neutralization ID50 vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 1 | 309 |
| 3.269scatterplots of Pseudovirus Neutralization ID50 vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 29 | 310 |
| 3.270scatterplots of Pseudovirus Neutralization ID50 vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 57 | 311 |
| 3.271scatterplots of Pseudovirus Neutralization ID80 vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 1 | 312 |
| 3.272scatterplots of Pseudovirus Neutralization ID80 vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 29 | 313 |

| | |
|---|-----|
| 3.273scatterplots of Pseudovirus Neutralization ID80 vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 57 | 314 |
| 3.274scatterplots of Binding Antibody to Spike vs Days Since the Day 29 Visit: by arm at day 1 | 315 |
| 3.275scatterplots of Binding Antibody to Spike vs Days Since the Day 29 Visit: by arm at day 29 | 316 |
| 3.276scatterplots of Binding Antibody to Spike vs Days Since the Day 29 Visit: by arm at day 57 | 317 |
| 3.277scatterplots of Binding Antibody to RBD vs Days Since the Day 29 Visit: by arm at day 1 | 318 |
| 3.278scatterplots of Binding Antibody to RBD vs Days Since the Day 29 Visit: by arm at day 29 | 319 |
| 3.279scatterplots of Binding Antibody to RBD vs Days Since the Day 29 Visit: by arm at day 57 | 320 |
| 3.280scatterplots of Pseudovirus Neutralization ID50 vs Days Since the Day 29 Visit vs Days Since the Day 29 Visit: by arm at day 1 | 321 |
| 3.281scatterplots of Pseudovirus Neutralization ID50 vs Days Since the Day 29 Visit vs Days Since the Day 29 Visit: by arm at day 29 | 322 |
| 3.282scatterplots of Pseudovirus Neutralization ID50 vs Days Since the Day 29 Visit: by arm at day 57 | 323 |
| 3.283scatterplots of Pseudovirus Neutralization ID80 vs Days Since the Day 29 Visit: by arm at day 1 | 324 |
| 3.284scatterplots of Pseudovirus Neutralization ID80 vs Days Since the Day 29 Visit: by arm at day 29 | 325 |
| 3.285scatterplots of Pseudovirus Neutralization ID80 vs Days Since the Day 29 Visit: by arm at day 57 | 326 |
| | |
| 4.1 Forest plots of hazard ratios per 10-fold increase in the marker among baseline negative vaccine recipients and subgroups with 95% point-wise confidence intervals. | 329 |
| 4.2 Forest plots of hazard ratios per 10-fold increase in the Day 57 binding Ab to spike markers among baseline negative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals. | 330 |
| 4.3 Forest plots of hazard ratios per 10-fold increase in the Day 57 binding Ab to RBD markers among baseline negative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals. | 330 |
| 4.4 Forest plots of hazard ratios per 10-fold increase in the Day 57 pseudo neut ID50 markers among baseline negative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals. | 331 |
| 4.5 Forest plots of hazard ratios per 10-fold increase in the Day 57 pseudo neut ID80 markers among baseline negative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals. | 331 |
| 4.6 Marginalized cumulative risk by Day 164 as functions of Day 57 markers (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (5 replicates). The horizontal lines indicate the overall cumulative risk of the placebo and vaccine arms by Day 164 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3, 1.6, 2.4, 15 for bAb Spike, bAb RBD, PsV nAb ID50, PsV nAb ID80, respectively. | 332 |
| 4.7 Controlled VE with sensitivity analysis as functions of Day 57 markers (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (5 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3, 1.6, 2.4, 15 for bAb Spike, bAb RBD, PsV nAb ID50, PsV nAb ID80, respectively. | 333 |

| | |
|---|-----|
| 4.8 Marginalized cumulative risk by Day 164 as functions of Day 57 markers above a threshold ($\geq s$) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (at least 5 cases are required, 5 replicates). The horizontal lines indicate the overall cumulative risk of the vaccine arm by Day 164 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3, 1.6, 2.4, 15 for bAb Spike, bAb RBD, PsV nAb ID50, PsV nAb ID80, respectively. | 334 |
| 4.9 Controlled VE as functions of Day 57 markers ($\geq s$) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (5 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3, 1.6, 2.4, 15 for bAb Spike, bAb RBD, PsV nAb ID50, PsV nAb ID80, respectively. | 335 |
| 4.10 Marginalized cumulative incidence rate curves for trichotomized Day 57 markers among baseline negative vaccine recipients. The gray line is the overall cumulative incidence rate curve in the placebo arm. | 336 |
| 5.1 Forest plots of hazard ratios per 10-fold increase in the marker among baseline negative vaccine recipients and subgroups with 95% point-wise confidence intervals. | 339 |
| 5.2 Forest plots of hazard ratios per 10-fold increase in the Day 29 binding Ab to spike markers among baseline negative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals. | 340 |
| 5.3 Forest plots of hazard ratios per 10-fold increase in the Day 29 binding Ab to RBD markers among baseline negative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals. | 340 |
| 5.4 Forest plots of hazard ratios per 10-fold increase in the Day 29 pseudo neut ID50 markers among baseline negative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals. | 341 |
| 5.5 Forest plots of hazard ratios per 10-fold increase in the Day 29 pseudo neut ID80 markers among baseline negative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals. | 341 |
| 5.6 Marginalized cumulative risk by Day 192 as functions of Day 29 markers ($=s$) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (5 replicates). The horizontal lines indicate the overall cumulative risk of the placebo and vaccine arms by Day 192 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3, 1.6, 2.4, 15 for bAb Spike, bAb RBD, PsV nAb ID50, PsV nAb ID80, respectively. | 342 |
| 5.7 Controlled VE with sensitivity analysis as functions of Day 29 markers ($=s$) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (5 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3, 1.6, 2.4, 15 for bAb Spike, bAb RBD, PsV nAb ID50, PsV nAb ID80, respectively. | 343 |
| 5.8 Marginalized cumulative risk by Day 192 as functions of Day 29 markers above a threshold ($\geq s$) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (at least 5 cases are required, 5 replicates). The horizontal lines indicate the overall cumulative risk of the vaccine arm by Day 192 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3, 1.6, 2.4, 15 for bAb Spike, bAb RBD, PsV nAb ID50, PsV nAb ID80, respectively. | 344 |
| 5.9 Controlled VE as functions of Day 29 markers ($\geq s$) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (5 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3, 1.6, 2.4, 15 for bAb Spike, bAb RBD, PsV nAb ID50, PsV nAb ID80, respectively. | 345 |

| | |
|---|-----|
| 5.10 Marginalized cumulative incidence rate curves for trichotomized Day 29 markers among base-line negative vaccine recipients. The gray line is the overall cumulative incidence rate curve in the placebo arm. | 346 |
| 6.1 Adjusted threshold-response function for a range of thresholds of the Day 57 Spike protein binding antibody levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. | 349 |
| 6.2 Adjusted threshold-response function for a range of thresholds of the Day 57 RBD binding antibody levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. | 350 |
| 6.3 Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. | 351 |
| 6.4 Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. | 352 |
| 6.5 Adjusted threshold-response function for a range of thresholds of the Day 29 Spike protein antibody levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. | 354 |
| 6.6 Adjusted threshold-response function for a range of thresholds of the Day 29 RBD binding antibody levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. | 355 |
| 6.7 Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. | 356 |
| 6.8 Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. | 357 |
| 6.9 Adjusted threshold-response function for a range of thresholds of the Day 57 Spike protein binding antibody levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 359 |
| 6.10 Adjusted threshold-response function for a range of thresholds of the Day 57 RBD binding antibody levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 360 |
| 6.11 Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 361 |
| 6.12 Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 362 |

| | |
|---|-----|
| 6.13 Adjusted threshold-response function for a range of thresholds of the Day 29 Spike protein antibody levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 364 |
| 6.14 Adjusted threshold-response function for a range of thresholds of the Day 29 RBD binding antibody levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 365 |
| 6.15 Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 366 |
| 6.16 Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 367 |
| 6.17 Adjusted threshold-response function for a range of thresholds of the Day 57 Spike protein binding antibody levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. | 369 |
| 6.18 Adjusted threshold-response function for a range of thresholds of the Day 57 RBD binding antibody levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. | 370 |
| 6.19 Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. | 371 |
| 6.20 Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. | 372 |
| 6.21 Adjusted threshold-response function for a range of thresholds of the Day 29 Spike protein antibody levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. | 374 |
| 6.22 Adjusted threshold-response function for a range of thresholds of the Day 29 RBD binding antibody levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. | 375 |
| 6.23 Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. | 376 |
| 6.24 Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. | 377 |
| 6.25 Adjusted threshold-response function for a range of thresholds of the Day 57 Spike protein binding antibody levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 379 |

| | |
|--|-----|
| 6.26 Adjusted threshold-response function for a range of thresholds of the Day 57 RBD binding antibody levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 380 |
| 6.27 Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 381 |
| 6.28 Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 382 |
| 6.29 Adjusted threshold-response function for a range of thresholds of the Day 29 Spike protein antibody levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 384 |
| 6.30 Adjusted threshold-response function for a range of thresholds of the Day 29 RBD binding antibody levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 385 |
| 6.31 Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 386 |
| 6.32 Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 387 |
| 7.1 Adjusted threshold-response function for a range of thresholds of the Day 57 Spike protein binding antibody levels with pointwise 95% confidence intervals. | 390 |
| 7.2 Adjusted threshold-response function for a range of thresholds of the Day 57 RBD binding antibody levels with pointwise 95% confidence intervals. | 391 |
| 7.3 Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals. | 392 |
| 7.4 Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals. | 393 |
| 7.5 Adjusted threshold-response function for a range of thresholds of the Day 29 Spike protein antibody levels with pointwise 95% confidence intervals. | 395 |
| 7.6 Adjusted threshold-response function for a range of thresholds of the Day 29 RBD binding antibody levels with pointwise 95% confidence intervals. | 396 |
| 7.7 Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals. | 397 |

| | | |
|------|---|-----|
| 7.8 | Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals. | 398 |
| 7.9 | Adjusted threshold-response function for a range of thresholds of the Day 57 Spike protein binding antibody levels with pointwise 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 400 |
| 7.10 | Adjusted threshold-response function for a range of thresholds of the Day 57 RBD binding antibody levels with pointwise 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 401 |
| 7.11 | Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 402 |
| 7.12 | Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 403 |
| 7.13 | Adjusted threshold-response function for a range of thresholds of the Day 29 Spike protein antibody levels with pointwise 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 405 |
| 7.14 | Adjusted threshold-response function for a range of thresholds of the Day 29 RBD binding antibody levels with pointwise 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 406 |
| 7.15 | Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 407 |
| 7.16 | Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 408 |
| 7.17 | Adjusted threshold-response function for a range of thresholds of the Day 57 Spike protein binding antibody levels with simultaneous 95% confidence intervals. | 410 |
| 7.18 | Adjusted threshold-response function for a range of thresholds of the Day 57 RBD binding antibody levels with simultaneous 95% confidence intervals. | 411 |
| 7.19 | Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals. | 412 |
| 7.20 | Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals. | 413 |
| 7.21 | Adjusted threshold-response function for a range of thresholds of the Day 29 Spike protein antibody levels with simultaneous 95% confidence intervals. | 415 |
| 7.22 | Adjusted threshold-response function for a range of thresholds of the Day 29 RBD binding antibody levels with simultaneous 95% confidence intervals. | 416 |
| 7.23 | Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals. | 417 |
| 7.24 | Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals. | 418 |

| | |
|---|-----|
| 7.25 Adjusted threshold-response function for a range of thresholds of the Day 57 Spike protein binding antibody levels with simultaneous 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 420 |
| 7.26 Adjusted threshold-response function for a range of thresholds of the Day 57 RBD binding antibody levels with simultaneous 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 421 |
| 7.27 Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 422 |
| 7.28 Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 423 |
| 7.29 Adjusted threshold-response function for a range of thresholds of the Day 29 Spike protein antibody levels with simultaneous 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 425 |
| 7.30 Adjusted threshold-response function for a range of thresholds of the Day 29 RBD binding antibody levels with simultaneous 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 426 |
| 7.31 Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 427 |
| 7.32 Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing. | 428 |
| 8.1 Marginalized risk as functions of Day 57 markers (==s) among baseline seronegative vaccine recipients with 95% bootstrap point-wise confidence bands (5 replicates) as modeled by GAM with automatic smoothness estimation. The horizontal lines indicate the overall cumulative risk of the vaccine and placebo arms by Day 164 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3, 1.6, 2.4, 15 for bAb Spike, bAb RBD, PsV nAb ID50, PsV nAb ID80, respectively. | 430 |
| 8.2 Marginalized risk as functions of Day 57 markers (==s) among baseline seronegative vaccine recipients with 95% bootstrap point-wise confidence bands (5 replicates) as modeled by GAM with automatic smoothness estimation. The horizontal lines indicate the overall cumulative risk of the vaccine arm by Day 164 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3, 1.6, 2.4, 15 for bAb Spike, bAb RBD, PsV nAb ID50, PsV nAb ID80, respectively. | 431 |
| 9.1 Marginalized risk as functions of Day 29 markers (==s) among baseline seronegative vaccine recipients with 95% bootstrap point-wise confidence bands (5 replicates) as modeled by GAM with automatic smoothness estimation. The horizontal lines indicate the overall cumulative risk of the vaccine and placebo arms by Day 192 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3, 1.6, 2.4, 15 for bAb Spike, bAb RBD, PsV nAb ID50, PsV nAb ID80, respectively. | 434 |

| | |
|---|-----|
| 9.2 Marginalized risk as functions of Day 29markers (=s) among baseline seronegative vaccine recipients with 95% bootstrap point-wise confidence bands (5 replicates) as modeled by GAM with automatic smoothness estimation. The horizontal lines indicate the overall cumulative risk of the vaccine arm by Day 192 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3, 1.6, 2.4,15 for bAb Spike, bAb RBD, PsV nAb ID50, PsV nAb ID80, respectively. | 435 |
|---|-----|

MOCH

MOCK

Chapter 1

Disclaimers

- The data presented in the analysis originated from the Moderna Sponsored mRNA-1273-P301 clinical study and are provided to NIAID in accordance with Clinical Trial Agreement between the parties. The study was funded in part by BARDA under Government Contract No. 75A50120C00034
- The preliminary immunogenicity data presented here do not reflect the Sponsors statistical analysis plan and therefore should not be interpreted as a protocol defined read-out of the clinical study.
- These data are not to be disclosed without written permission of Moderna.

MOCK

Chapter 2

Summary Tables

2.1 Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Negative Per-Protocol Cohort

Table 1. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Negative Per-Protocol Cohort

| Characteristics | Vaccine (N = 747) | Placebo (N = 138) | Total (N = 885) |
|---|----------------------|----------------------|--------------------|
| Age | | | |
| Age < 65 | 357 (47.8%) | 72 (52.2%) | 429 (48.5%) |
| Age ≥ 65 | 390 (52.2%) | 66 (47.8%) | 456 (51.5%) |
| Mean (Range) | 58.5 (18.0, 85.0) | 58.3 (18.0, 85.0) | 58.5 (18.0, 85.0) |
| BMI | | | |
| Mean ± SD | 29.7 ± 6.6 | 31.4 ± 6.3 | 30.0 ± 6.6 |
| Risk for Severe Covid-19 | | | |
| At-risk | 381 (51.0%) | 71 (51.4%) | 452 (51.1%) |
| Not at-risk | 366 (49.0%) | 67 (48.6%) | 433 (48.9%) |
| Age, Risk for Severe Covid-19 | | | |
| Age < 65 At-risk | 185 (24.8%) | 36 (26.1%) | 221 (25.0%) |
| Age < 65 Not at-risk | 172 (23.0%) | 36 (26.1%) | 208 (23.5%) |
| Age ≥ 65 | 390 (52.2%) | 66 (47.8%) | 456 (51.5%) |
| Sex | | | |
| Female | 427 (57.2%) | 75 (54.3%) | 502 (56.7%) |
| Male | 320 (42.8%) | 63 (45.7%) | 383 (43.3%) |
| Hispanic or Latino ethnicity | | | |
| Hispanic or Latino | 99 (13.3%) | 20 (14.5%) | 119 (13.4%) |
| Not Hispanic or Latino | 623 (83.4%) | 113 (81.9%) | 736 (83.2%) |
| Not reported and unknown | 25 (3.3%) | 5 (3.6%) | 30 (3.4%) |
| Race | | | |
| White | 397 (53.1%) | 74 (53.6%) | 471 (53.2%) |
| Black or African American | 184 (24.6%) | 40 (29.0%) | 224 (25.3%) |
| Asian | 56 (7.5%) | 10 (7.2%) | 66 (7.5%) |
| American Indian or Alaska Native | 16 (2.1%) | 2 (1.4%) | 18 (2.0%) |
| Native Hawaiian or Other Pacific Islander | 17 (2.3%) | 2 (1.4%) | 19 (2.1%) |

(continued)

| Characteristics | Vaccine (N = 747) | Placebo (N = 138) | Total (N = 885) |
|--------------------------|----------------------|----------------------|--------------------|
| Multiracial | 57 (7.6%) | 8 (5.8%) | 65 (7.3%) |
| Other | 16 (2.1%) | 1 (0.7%) | 17 (1.9%) |
| Not reported and unknown | 4 (0.5%) | 1 (0.7%) | 5 (0.6%) |
| White Non-Hispanic | 370 (49.5%) | 63 (45.7%) | 433 (48.9%) |
| Communities of Color | 377 (50.5%) | 75 (54.3%) | 452 (51.1%) |

This table summarizes the random subcohort, which was randomly sampled from the per-protocol cohort. The sampling was stratified by 24 strata defined by enrollment characteristics: Assigned treatment arm × Baseline SARS-CoV-2 naïve vs. non-naïve status (defined by serostatus and NAAT testing) × Randomization strata (Age < 65 and at-risk, Age < 65 and not at-risk, Age ≥ 65) × Communities of color (Yes/No) defined by White Non-Hispanic vs. all others (following the primary COVE trial paper).

MOCH

2.2 Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Positive Per-Protocol Cohort

Table 2. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Positive Per-Protocol Cohort

| Characteristics | Vaccine (N = 234) | Placebo (N = 241) | Total (N = 475) |
|---|----------------------|----------------------|--------------------|
| Age | | | |
| Age < 65 | 114 (48.7%) | 120 (49.8%) | 234 (49.3%) |
| Age ≥ 65 | 120 (51.3%) | 121 (50.2%) | 241 (50.7%) |
| Mean (Range) | 58.3 (18.0, 85.0) | 56.3 (18.0, 85.0) | 57.3 (18.0, 85.0) |
| BMI | | | |
| Mean ± SD | 29.7 ± 7.5 | 30.0 ± 6.6 | 29.9 ± 7.0 |
| Risk for Severe Covid-19 | | | |
| At-risk | 111 (47.4%) | 117 (48.5%) | 228 (48.0%) |
| Not at-risk | 123 (52.6%) | 124 (51.5%) | 247 (52.0%) |
| Age, Risk for Severe Covid-19 | | | |
| Age < 65 At-risk | 56 (23.9%) | 59 (24.5%) | 115 (24.2%) |
| Age < 65 Not at-risk | 58 (24.8%) | 61 (25.3%) | 119 (25.1%) |
| Age ≥ 65 | 120 (51.3%) | 121 (50.2%) | 241 (50.7%) |
| Sex | | | |
| Female | 139 (59.4%) | 133 (55.2%) | 272 (57.3%) |
| Male | 95 (40.6%) | 108 (44.8%) | 203 (42.7%) |
| Hispanic or Latino ethnicity | | | |
| Hispanic or Latino | 31 (13.2%) | 34 (14.1%) | 65 (13.7%) |
| Not Hispanic or Latino | 194 (82.9%) | 201 (83.4%) | 395 (83.2%) |
| Not reported and unknown | 9 (3.8%) | 6 (2.5%) | 15 (3.2%) |
| Race | | | |
| White | 126 (53.8%) | 129 (53.5%) | 255 (53.7%) |
| Black or African American | 58 (24.8%) | 45 (18.7%) | 103 (21.7%) |
| Asian | 19 (8.1%) | 27 (11.2%) | 46 (9.7%) |
| American Indian or Alaska Native | 10 (4.3%) | 7 (2.9%) | 17 (3.6%) |
| Native Hawaiian or Other Pacific Islander | 4 (1.7%) | 2 (0.8%) | 6 (1.3%) |
| Multiracial | 10 (4.3%) | 16 (6.6%) | 26 (5.5%) |
| Other | 7 (3.0%) | 13 (5.4%) | 20 (4.2%) |
| Not reported and unknown | | 2 (0.8%) | 2 (0.4%) |
| White Non-Hispanic | 118 (50.4%) | 121 (50.2%) | 239 (50.3%) |
| Communities of Color | 116 (49.6%) | 120 (49.8%) | 236 (49.7%) |

This table summarizes the random subcohort, which was randomly sampled from the per-protocol cohort. The sampling was stratified by 24 strata defined by enrollment characteristics: Assigned treatment arm × Baseline SARS-CoV-2 naïve vs. non-naïve status (defined by serostatus and NAAT testing) × Randomization strata (Age < 65 and at-risk, Age < 65 and not at-risk, Age ≥ 65) × Communities of color (Yes/No) defined by White Non-Hispanic vs. all others (following the primary COVE trial paper).

2.3 Sample Sizes of Baseline Strata for Correlates of Risk Analysis

Table 3. Sample Sizes of Baseline Strata for Correlates of Risk Analysis

| Per-protocol Cases and Non-Cases (Moderna Trial) | | | | | | | | | | | | | | | | | | |
|--|------------------------------|-----|----|----|-----|----|----|-----|----|------------------------------|----|----|----|----|----|----|----|----|
| | Baseline SARS-CoV-2 Negative | | | | | | | | | Baseline SARS-CoV-2 Positive | | | | | | | | |
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
| Vaccine | | | | | | | | | | | | | | | | | | |
| Day 29 Cases | 8 | 18 | 6 | 2 | 7 | 0 | 3 | 12 | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 |
| Day 57 Cases | 8 | 18 | 4 | 2 | 7 | 0 | 1 | 9 | 3 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 |
| Non-Cases | 153 | 235 | 69 | 78 | 106 | 35 | 67 | 105 | 39 | 48 | 72 | 26 | 24 | 32 | 12 | 23 | 35 | 11 |
| Placebo | | | | | | | | | | | | | | | | | | |
| Day 29 Cases | 141 | 329 | 77 | 48 | 109 | 31 | 87 | 243 | 55 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 |
| Day 57 Cases | 132 | 306 | 72 | 37 | 93 | 27 | 61 | 198 | 42 | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 0 |
| Non-Cases | 21 | 34 | 9 | 16 | 16 | 2 | 16 | 18 | 3 | 43 | 77 | 32 | 19 | 39 | 16 | 22 | 38 | 9 |

Demographic covariate strata:

- | | |
|----------------------------------|--------------------------------------|
| 1. Age \geq 65 Minority | 6. Age < 65 At-risk Unknown |
| 2. Age \geq 65 Non-Minority | 7. Age < 65 Not At-risk Minority |
| 3. Age \geq 65 Unknown | 8. Age < 65 Not At-risk Non-Minority |
| 4. Age < 65 At-risk Minority | 9. Age < 65 Not At-risk Unknown |
| 5. Age < 65 At-risk Non-Minority | |

Minority includes Blacks or African Americans, Hispanics or Latinos, American Indians or Alaska Natives, Native Hawaiians, and other Pacific Islanders.

Non-Minority includes all other races with observed race (Asian, Multiracial, White, Other) and observed ethnicity Not Hispanic or Latino.

Unknown includes unknown, unreported race or ethnicity.

Cases for Day 29 marker correlates analyses are per-protocol vaccine recipients with the symptomatic infection COVID-19 primary endpoint diagnosed starting 7 days after the Day 29 study visit. Cases for Day 57 marker correlates analyses are per-protocol vaccine recipients with the symptomatic infection COVID-19 primary endpoint diagnosed starting 7 days after the Day 57 study visit. Non-cases are per-protocol participants sampled into the random subcohort with no COVID primary endpoint up to the time of data cut and no evidence of SARS-CoV-2 infection up to six days post Day 57 visit.

The table shows the numbers of cases sampled into the subcohort within baseline covariate strata.

2.4 Antibody levels in the baseline SARS-CoV-2 negative per-protocol cohort (vaccine recipients)

Table 4. Antibody levels in the baseline SARS-CoV-2 negative per-protocol cohort (vaccine recipients)

| Visit | Marker | Baseline SARS-CoV-2 Negative Vaccine Recipients | | | | | | Comparison | |
|--------|------------------------|---|------------------------------------|-------------------------------|-----|--|-------------------------------|-----------------------|----------------------|
| | | Cases* | | Non-Cases/Control | | Resp Rate Difference | GMTR/GMCR | | |
| N | Resp rate | N | Resp rate | GMT/GMC | | | | | |
| Day 29 | Pseudovirus-nAb ID80 | 59 | 35.6/60 = 59.3% (46.2%, 71.3%) | 21.18 (17.33, 25.87) | 744 | 6530.6/11070 = 59.0% (54.4%, 63.4%) | 25.97 (23.98, 28.13) | 0 (-0.14, 0.13) | 0.82 (0.66, 1.01) |
| Day 29 | Pseudovirus-nAb ID50 | 59 | 53.9/60 = 89.8% (78.9%, 95.4%) | 16.19 (12.51, 20.95) | 744 | 9932/11070 = 89.7% (86.2%, 92.4%) | 17.35 (15.85, 18.99) | 0 (-0.11, 0.07) | 0.93 (0.71, 1.23) |
| Day 29 | Anti RBD IgG (IU/ml) | 59 | 60/60 = 100.0% (100.0%, 100.0%) | 456.66 (292.67, 712.53) | 744 | 10896.8/11070 = 98.4% (96.6%, 99.3%) | 473.53 (412.98, 542.96) | 0.02 (0.01, 0.03) | 0.96 (0.61, 1.54) |
| Day 29 | Anti Spike IgG (IU/ml) | 59 | 60/60 = 100.0% (100.0%, 100.0%) | 236.57 (169.47, 330.25) | 744 | 10981.5/11070 = 99.2% (97.7%, 99.7%) | 266.03 (238.38, 296.89) | 0.01 (0, 0.02) | 0.89 (0.63, 1.26) |
| Day 29 | Anti N IgG (IU/ml) | 59 | 35.6/60 = 59.3% (46.2%, 71.3%) | 39.18 (24.94, 61.55) | 744 | 6848.9/11070 = 61.9% (57.3%, 66.2%) | 36.77 (31.08, 43.49) | -0.03 (-0.16, 0.1) | 1.07 (0.66, 1.73) |
| Day 57 | Pseudovirus-nAb ID80 | 52 | 52/52 = 100.0% (100.0%, 100.0%) | 408.70 (310.06, 538.71) | 744 | 11065/11065 = 100.0% (100.0%, 100.0%) | 564.67 (511.70, 623.12) | 0 (0, 0) | 0.72 (0.54, 0.97) |
| Day 57 | Pseudovirus-nAb ID50 | 52 | 52/52 = 100.0% (100.0%, 100.0%) | 320.14 (230.41, 444.83) | 744 | 11065/11065 = 100.0% (100.0%, 100.0%) | 427.25 (383.62, 475.84) | 0 (0, 0) | 0.75 (0.53, 1.06) |
| Day 57 | Anti RBD IgG (IU/ml) | 52 | 52/52 = 100.0% (100.0%, 100.0%) | 3325.76 (2232.06, 4955.38) | 744 | 11045.2/11065 = 99.8% (98.7%, 100.0%) | 3599.25 (3171.86, 4084.22) | 0 (0, 0.01) | 0.92 (0.61, 1.40) |
| Day 57 | Anti Spike IgG (IU/ml) | 52 | 52/52 = 100.0% (100.0%, 100.0%) | 1847.33 (1337.98, 2550.57) | 744 | 11065/11065 = 100.0% (100.0%, 100.0%) | 2668.40 (2364.64, 3011.17) | 0 (0, 0) | 0.69 (0.49, 0.98) |

| | | | | | | | | | |
|-----|--------------------|----|------------------------------------|--------------------------|-----|---|---------------------------|-----------------------|----------------------|
| Day | Anti N IgG (IU/ml) | 52 | $37/52 = 71.2\%$ (57.2%, 82.0%) | 71.78 (43.87, 117.44) | 744 | $8998.4/11065 = 81.3\%$ (77.3%, 84.8%) | 110.30 (94.07, 129.33) | -0.1 (-0.25, 0.01) | 0.65 (0.39, 1.09) |
|-----|--------------------|----|------------------------------------|--------------------------|-----|---|---------------------------|-----------------------|----------------------|

Cases for Day 29 marker correlates analyses are baseline negative per-protocol vaccine recipients with the symptomatic infection COVID-19 primary endpoint diagnosed starting 7 days after the Day 29 study visit. Cases for Day 57 marker correlates analyses are baseline negative per-protocol vaccine recipients with the symptomatic infection COVID-19 primary endpoint diagnosed starting 7 days after the Day 57 study visit.

N is the number of cases sampled into the subcohort within baseline covariate strata.

The denominator in Resp Rate is the number of participants in the whole per-protocol cohort within baseline covariate strata, calculated using inverse probability weighting.



2.5 Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (vaccine recipients)

Table 5. Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (vaccine recipients)


| Visit | Marker | Baseline SARS-CoV-2 Positive Vaccine Recipients | | | | | | Comparison | |
|--------|------------------------|---|----------------------------------|----------------------------------|-----|---|--------------------------------|------------------------|----------------------|
| | | Cases* | | Non-Cases/Control | | | | Resp Rate Difference | GMTR/GMCR |
| | | N | Resp rate | GMT/GMC | N | Resp rate | GMT/GMC | | |
| Day 29 | Pseudovirus-nAb ID80 | 3 | 3.3/5 = 66.7% (0.6%, 99.8%) | 28.17 (20.25, 39.20) | 234 | 904.7/1218.1 = 74.3% (66.3%, 80.9%) | 51.20 (44.64, 58.73) | -0.08 (-0.74, 0.27) | 0.55 (0.38, 0.79) |
| Day 29 | Pseudovirus-nAb ID50 | 3 | 5/5 = 100.0% (100.0%, 100.0%) | 37.31 (35.33, 39.40) | 234 | 1159.7/1218.1 = 95.2% (89.2%, 97.9%) | 32.70 (28.11, 38.04) | 0.05 (0.02, 0.11) | 1.14 (0.97, 1.34) |
| Day 29 | Anti RBD IgG (IU/ml) | 3 | 5/5 = 100.0% (100.0%, 100.0%) | 622.59 (124.89, 3103.56) | 234 | 1213.5/1218.1 = 99.6% (97.3%, 99.9%) | 823.96 (640.00, 1060.79) | 0 (0, 0.03) | 0.76 (0.15, 3.84) |
| Day 29 | Anti Spike IgG (IU/ml) | 3 | 5/5 = 100.0% (100.0%, 100.0%) | 180.93 (156.70, 208.91) | 234 | 1209.6/1218.1 = 99.3% (95.1%, 99.9%) | 474.27 (397.60, 565.71) | 0.01 (0, 0.05) | 0.38 (0.30, 0.48) |
| Day 29 | Anti N IgG (IU/ml) | 3 | 5/5 = 100.0% (100.0%, 100.0%) | 220.52 (99.97, 486.42) | 234 | 928.1/1218.1 = 76.2% (68.6%, 82.4%) | 70.68 (55.09, 90.70) | 0.24 (0.18, 0.31) | 3.12 (1.36, 7.15) |
| Day 57 | Pseudovirus-nAb ID80 | 3 | 5/5 = 100.0% (100.0%, 100.0%) | 1156.48 (486.62, 2748.44) | 233 | 1229/1229 = 100.0% (100.0%, 100.0%) | 1559.92 (1333.89, 1824.26) | 0 (0, 0) | 0.74 (0.31, 1.79) |
| Day 57 | Pseudovirus-nAb ID50 | 3 | 5/5 = 100.0% (100.0%, 100.0%) | 493.08 (319.26, 761.53) | 233 | 1229/1229 = 100.0% (100.0%, 100.0%) | 1227.59 (1000.73, 1505.88) | 0 (0, 0) | 0.40 (0.25, 0.65) |
| Day 57 | Anti RBD IgG (IU/ml) | 3 | 5/5 = 100.0% (100.0%, 100.0%) | 15558.50 (14386.64, 16825.81) | 233 | 1229/1229 = 100.0% (100.0%, 100.0%) | 8619.19 (7266.78, 10223.28) | 0 (0, 0) | 1.81 (1.50, 2.18) |
| Day 57 | Anti Spike IgG (IU/ml) | 3 | 5/5 = 100.0% (100.0%, 100.0%) | 4871.27 (3719.87, 6379.06) | 233 | 1229/1229 = 100.0% (100.0%, 100.0%) | 5665.25 (4956.22, 6475.72) | 0 (0, 0) | 0.86 (0.64, 1.16) |

| | | | | | | | | | |
|-----------|--------------------|---|-------------------------------------|----------------------------|-----|--|----------------------------|----------------------|----------------------|
| Day 57 | Anti N IgG (IU/ml) | 3 | $5/5 = 100.0\%$ (100.0%, 100.0%) | 293.21 (150.76, 570.25) | 233 | $1182.5/1229 = 96.2\%$ (90.6%, 98.5%) | 248.12 (202.53, 303.97) | 0.04 (0.01, 0.09) | 1.18 (0.59, 2.37) |
|-----------|--------------------|---|-------------------------------------|----------------------------|-----|--|----------------------------|----------------------|----------------------|

The SAP does not specify correlates analyses in baseline positive vaccine recipients. This table summarizes descriptively the same information for baseline positive vaccine recipients that was summarized for baseline negative vaccine recipients. Cases for Day 29 markers are baseline positive per-protocol vaccine recipients with the symptomatic infection COVID-19 primary endpoint diagnosed starting 7 days after the Day 29 study visit. Cases for Day 57 markers are baseline positive per-protocol vaccine recipients with the symptomatic infection COVID-19 primary endpoint diagnosed starting 7 days after the Day 57 study visit. Non-cases/Controls are baseline positive per-protocol vaccine recipients sampled into the random subcohort with no COVID-19 endpoint diagnosis by the time of data-cut.

N is the number of cases sampled into the subcohort within baseline covariate strata.

The denominator in Resp Rate is the number of participants in the whole per-protocol cohort within baseline covariate strata, calculated using inverse probability weighting.



2.6 Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (placebo recipients)

Table 6. Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (placebo recipients)

| Visit | Marker | Baseline SARS-CoV-2 Positive Placebo Recipients | | | | | | Comparison | |
|--------|------------------------|---|-------------------------------|-----------|--|-------------------------------|------------------------|-----------------------|-----------|
| | | Cases* | | | Non-Cases/Control | | | Resp Rate Difference | GMTR/GMCR |
| N | Resp rate | GMT/GMC | N | Resp rate | GMT/GMC | | | | |
| Day 29 | Pseudovirus-nAb ID80 | 5 3/5 = 60.0% (10.6%, 95.0%) | 19.58 (9.63, 39.79) | 238 | 442.9/1121 = 39.5% (32.4%, 47.1%) | 20.38 (17.86, 23.27) | 0.2 (-0.29, 0.56) | 0.96 (0.47, 1.98) | |
| Day 29 | Pseudovirus-nAb ID50 | 5 2/5 = 40.0% (5.0%, 89.4%) | 4.46 (1.50, 13.28) | 238 | 896.5/1121 = 80.0% (72.4%, 85.9%) | 11.68 (9.90, 13.77) | -0.4 (-0.75, 0.1) | 0.38 (0.13, 1.15) | |
| Day 29 | Anti RBD IgG (IU/ml) | 5 5/5 = 100.0% (100.0%, 100.0%) | 498.48 (77.45, 3208.22) | 238 | 1060/1121 = 94.6% (88.4%, 97.5%) | 306.92 (232.82, 404.62) | 0.05 (0.02, 0.12) | 1.62 (0.25, 10.67) | |
| Day 29 | Anti Spike IgG (IU/ml) | 5 5/5 = 100.0% (100.0%, 100.0%) | 266.06 (74.76, 946.84) | 238 | 1085.9/1121 = 96.9% (91.9%, 98.8%) | 170.13 (136.41, 212.19) | 0.03 (0.01, 0.08) | 1.56 (0.43, 5.67) | |
| Day 29 | Anti N IgG (IU/ml) | 5 3/5 = 60.0% (10.6%, 95.0%) | 11.78 (2.03, 68.41) | 238 | 603/1121 = 53.8% (45.9%, 61.5%) | 26.96 (20.32, 35.77) | 0.06 (-0.44, 0.42) | 0.44 (0.07, 2.60) | |
| Day 57 | Pseudovirus-nAb ID80 | 5 5/5 = 100.0% (100.0%, 100.0%) | 288.29 (114.87, 723.51) | 238 | 1119/1119 = 100.0% (100.0%, 100.0%) | 462.73 (395.43, 541.48) | 0 (0, 0) | 0.62 (0.24, 1.58) | |
| Day 57 | Pseudovirus-nAb ID50 | 5 5/5 = 100.0% (100.0%, 100.0%) | 629.06 (128.64, 3076.16) | 238 | 1119/1119 = 100.0% (100.0%, 100.0%) | 313.97 (258.96, 380.65) | 0 (0, 0) | 2.00 (0.40, 9.91) | |
| Day 57 | Anti RBD IgG (IU/ml) | 5 5/5 = 100.0% (100.0%, 100.0%) | 1704.47 (253.44, 11462.91) | 238 | 1119/1119 = 100.0% (100.0%, 100.0%) | 2656.74 (2066.29, 3415.92) | 0 (0, 0) | 0.64 (0.09, 4.39) | |
| Day 57 | Anti Spike IgG (IU/ml) | 5 5/5 = 100.0% (100.0%, 100.0%) | 1648.06 (332.52, 8168.38) | 238 | 1119/1119 = 100.0% (100.0%, 100.0%) | 1953.05 (1538.23, 2479.73) | 0 (0, 0) | 0.84 (0.17, 4.26) | |
| Day 57 | Anti N IgG (IU/ml) | 5 3/5 = 60.0% (10.6%, 95.0%) | 49.66 (3.50, 703.93) | 238 | 865.3/1119 = 77.3% (69.5%, 83.6%) | 94.81 (70.11, 128.23) | -0.17 (-0.67, 0.19) | 0.52 (0.04, 7.55) | |

(continued)

| Visit | Marker | N | Resp rate | GMT/GMC | N | Resp rate | GMT/GMC | Resp Rate Difference | GMTR/GMCR |
|-------|--------|---|-----------|---------|---|-----------|---------|----------------------|-----------|
|-------|--------|---|-----------|---------|---|-----------|---------|----------------------|-----------|

The SAP does not specify correlates analyses in baseline positive placebo recipients. This table summarizes descriptively the same information for baseline positive placebo recipients that was summarized for baseline negative and positive vaccine recipients. Cases for Day 29 markers are baseline positive per-protocol placebo recipients with the symptomatic infection COVID-19 primary endpoint diagnosed starting 7 days after the Day 29 study visit. Cases for Day 57 markers are baseline positive per-protocol placebo recipients with the symptomatic infection COVID-19 primary endpoint diagnosed starting 7 days after the Day 57 study visit. Non-cases/Controls are baseline positive per-protocol placebo recipients sampled into the random subcohort with no COVID-19 endpoint diagnosis by the time of data-cut.

N is the number of cases sampled into the subcohort within baseline covariate strata.

The denominator in Resp Rate is the number of participants in the whole per-protocol cohort within baseline covariate strata, calculated using inverse probability weighting.

MOCK

Chapter 3

Graphical Descriptions of Antibody Marker Data

3.1 Boxplots




Figure 3.1: Boxplots of D57 Ab markers: vaccine arm. The three dashed lines in each figure are ULOQ, LLOQ, and LLOD, from top to bottom respectively.




Figure 3.2: Boxplots of D57 fold-rise over D1 Ab markers: vaccine arm.




Figure 3.3: Boxplots of D29 Ab markers: vaccine arm. The three dashed lines in each figure are ULOQ, LLOQ, and LLOD, from top to bottom respectively.




Figure 3.4: Boxplots of D29 fold-rise over D1 Ab markers: vaccine arm.

3.2 Weighted RCDF plots




Figure 3.5: RCDF plots for D57 Ab markers by treatment arm.




Figure 3.6: RCDF plots for D57 fold-rise over D1 Ab markers by treatment arm.




Figure 3.7: RCDF plots for D29 Ab markers by treatment arm.




Figure 3.8: RCDF plots for D29 fold-rise over D1 Ab markers by treatment arm.

3.3 Weighted RCDF plots of threshold correlate concentration for vaccine efficacy




Figure 3.9: Marker RCDF of D57 anti-Spike binding Ab: vaccine arm

3.3. WEIGHTED RCDF PLOTS OF THRESHOLD CORRELATE CONCENTRATION FOR VACCINE EFFICACY51




Figure 3.10: Marker RCDF of D57 anti-RBD binding Ab: vaccine arm




Figure 3.11: Marker RCDF of D57 PsV-nAb ID50: vaccine arm

3.3. WEIGHTED RCDF PLOTS OF THRESHOLD CORRELATE CONCENTRATION FOR VACCINE EFFICACY53




Figure 3.12: Marker RCDF of D57 PsV-nAb ID80: vaccine arm

3.4 Spaghetti plots




Figure 3.13: Spaghetti Plots of Marker Trajectory: vaccine arm

3.5 Violin and line plots




Figure 3.14: lineplots of Binding Antibody to Spike: baseline negative placebo arm (version 1)




Figure 3.15: lineplots of Binding Antibody to Spike: baseline negative vaccine arm (version 1)




Figure 3.16: lineplots of Binding Antibody to RBD: baseline negative placebo arm (version 1)




Figure 3.17: lineplots of Binding Antibody to RBD: baseline negative vaccine arm (version 1)




Figure 3.18: lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm (version 1)




Figure 3.19: lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm (version 1)




Figure 3.20: lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm (version 1)




Figure 3.21: lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm (version 1)




Figure 3.22: violinplots of Binding Antibody to Spike: baseline negative placebo arm (version 1)




Figure 3.23: violinplots of Binding Antibody to Spike: baseline negative vaccine arm (version 1)




Figure 3.24: violinplots of Binding Antibody to RBD: baseline negative placebo arm (version 1)




Figure 3.25: violinplots of Binding Antibody to RBD: baseline negative vaccine arm (version 1)




Figure 3.26: violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm (version 1)




Figure 3.27: violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm (version 1)




Figure 3.28: violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm (version 1)




Figure 3.29: violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm (version 1)




Figure 3.30: lineplots of Binding Antibody to Spike: baseline negative placebo arm (version 2)




Figure 3.31: lineplots of Binding Antibody to Spike: baseline negative vaccine arm (version 2)




Figure 3.32: lineplots of Binding Antibody to RBD: baseline negative placebo arm (version 2)




Figure 3.33: lineplots of Binding Antibody to RBD: baseline negative vaccine arm (version 2)




Figure 3.34: lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm (version 2)




Figure 3.35: lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm (version 2)




Figure 3.36: lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm (version 2)




Figure 3.37: lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm (version 2)




Figure 3.38: violinplots of Binding Antibody to Spike: baseline negative placebo arm (version 2)




Figure 3.39: violinplots of Binding Antibody to Spike: baseline negative vaccine arm (version 2)




Figure 3.40: violinplots of Binding Antibody to RBD: baseline negative placebo arm (version 2)




Figure 3.41: violinplots of Binding Antibody to RBD: baseline negative vaccine arm (version 2)




Figure 3.42: violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm (version 2)




Figure 3.43: violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm (version 2)




Figure 3.44: violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm (version 2)




Figure 3.45: violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm (version 2)




Figure 3.46: lineplots of Binding Antibody to Spike: baseline negative placebo arm by age (version 1)




Figure 3.47: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by age (version 1)




Figure 3.48: lineplots of Binding Antibody to RBD: baseline negative placebo arm by age (version 1)




Figure 3.49: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by age (version 1)




Figure 3.50: lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age (version 1)




Figure 3.51: lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age (version 1)




Figure 3.52: lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age (version 1)




Figure 3.53: lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age (version 1)




Figure 3.54: violinplots of Binding Antibody to Spike: baseline negative placebo arm by age (version 1)




Figure 3.55: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by age (version 1)




Figure 3.56: violinplots of Binding Antibody to RBD: baseline negative placebo arm by age (version 1)




Figure 3.57: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by age (version 1)




Figure 3.58: violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age (version 1)




Figure 3.59: violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age (version 1)




Figure 3.60: violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age (version 1)




Figure 3.61: violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age (version 1)




Figure 3.62: lineplots of Binding Antibody to Spike: baseline negative placebo arm by age (version 2)




Figure 3.63: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by age (version 2)




Figure 3.64: lineplots of Binding Antibody to RBD: baseline negative placebo arm by age (version 2)




Figure 3.65: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by age (version 2)




Figure 3.66: lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age (version 2)




Figure 3.67: lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age (version 2)




Figure 3.68: lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age (version 2)




Figure 3.69: lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age (version 2)




Figure 3.70: violinplots of Binding Antibody to Spike: baseline negative placebo arm by age (version 2)




Figure 3.71: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by age (version 2)




Figure 3.72: violinplots of Binding Antibody to RBD: baseline negative placebo arm by age (version 2)




Figure 3.73: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by age (version 2)




Figure 3.74: violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age (version 2)




Figure 3.75: violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age (version 2)




Figure 3.76: violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age (version 2)




Figure 3.77: violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age (version 2)




Figure 3.78: lineplots of Binding Antibody to Spike: baseline negative placebo arm by risk condition (version 1)




Figure 3.79: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by risk condition (version 1)




Figure 3.80: lineplots of Binding Antibody to RBD: baseline negative placebo arm by risk condition (version 1)




Figure 3.81: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by risk condition (version 1)




Figure 3.82: lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by risk condition (version 1)




Figure 3.83: lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by risk condition (version 1)




Figure 3.84: lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by risk condition (version 1)




Figure 3.85: lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by risk condition (version 1)




Figure 3.86: violinplots of Binding Antibody to Spike: baseline negative placebo arm by risk condition (version 1)




Figure 3.87: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by risk condition (version 1)




Figure 3.88: violinplots of Binding Antibody to RBD: baseline negative placebo arm by risk condition (version 1)




Figure 3.89: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by risk condition (version 1)




Figure 3.90: violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by risk condition (version 1)




Figure 3.91: violinplots of Pseudovirus Neutralization ID₅₀: baseline negative vaccine arm by risk condition (version 1)




Figure 3.92: violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by risk condition (version 1)




Figure 3.93: violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by risk condition (version 1)




Figure 3.94: lineplots of Binding Antibody to Spike: baseline negative placebo arm by risk condition (version 2)




Figure 3.95: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by risk condition (version 2)




Figure 3.96: lineplots of Binding Antibody to RBD: baseline negative placebo arm by risk condition (version 2)




Figure 3.97: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by risk condition (version 2)




Figure 3.98: lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by risk condition (version 2)




Figure 3.99: lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by risk condition (version 2)




Figure 3.100: lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by risk condition (version 2)




Figure 3.101: lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by risk condition (version 2)




Figure 3.102: violinplots of Binding Antibody to Spike: baseline negative placebo arm by risk condition (version 2)




Figure 3.103: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by risk condition (version 2)




Figure 3.104: violinplots of Binding Antibody to RBD: baseline negative placebo arm by risk condition (version 2)




Figure 3.105: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by risk condition (version 2)




Figure 3.106: violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by risk condition (version 2)




Figure 3.107: violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by risk condition (version 2)




Figure 3.108: violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by risk condition (version 2)




Figure 3.109: violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by risk condition (version 2)




Figure 3.110: lineplots of Binding Antibody to Spike: baseline negative placebo arm by age and risk condition (version 1)




Figure 3.111: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by age and risk condition (version 1)




Figure 3.112: lineplots of Binding Antibody to RBD: baseline negative placebo arm by age and risk condition (version 1)




Figure 3.113: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by age and risk condition (version 1)




Figure 3.114: lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age and risk condition (version 1)




Figure 3.115: lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age and risk condition (version 1)




Figure 3.116: lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age and risk condition (version 1)




Figure 3.117: lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age and risk condition (version 1)




Figure 3.118: violinplots of Binding Antibody to Spike: baseline negative placebo arm by age and risk condition (version 1)




Figure 3.119: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by age and risk condition (version 1)




Figure 3.120: violinplots of Binding Antibody to RBD: baseline negative placebo arm by age and risk condition (version 1)




Figure 3.121: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by age and risk condition (version 1)




Figure 3.122: violinplots of Pseudovirus Neutralization ID₅₀: baseline negative placebo arm by age and risk condition (version 1)




Figure 3.123: violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age and risk condition (version 1)




Figure 3.124: violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age and risk condition (version 1)




Figure 3.125: violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age and risk condition (version 1)




Figure 3.126: lineplots of Binding Antibody to Spike: baseline negative placebo arm by age and risk condition (version 2)




Figure 3.127: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by age and risk condition (version 2)




Figure 3.128: lineplots of Binding Antibody to RBD: baseline negative placebo arm by age and risk condition (version 2)




Figure 3.129: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by age and risk condition (version 2)




Figure 3.130: lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age and risk condition (version 2)




Figure 3.131: lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by age and risk condition (version 2)




Figure 3.132: lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age and risk condition (version 2)




Figure 3.133: lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age and risk condition (version 2)




Figure 3.134: violinplots of Binding Antibody to Spike: baseline negative placebo arm by age and risk condition (version 2)




Figure 3.135: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by age and risk condition (version 2)




Figure 3.136: violinplots of Binding Antibody to RBD: baseline negative placebo arm by age and risk condition (version 2)




Figure 3.137: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by age and risk condition (version 2)




Figure 3.138: violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by age and risk condition (version 2)




Figure 3.139: violinplots of Pseudovirus Neutralization ID₅₀: baseline negative vaccine arm by age and risk condition (version 2)




Figure 3.140: violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by age and risk condition (version 2)




Figure 3.141: violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by age and risk condition (version 2)




Figure 3.142: lineplots of Binding Antibody to Spike: baseline negative placebo arm by sex assigned at birth (version 1)




Figure 3.143: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by sex assigned at birth (version 1)




Figure 3.144: lineplots of Binding Antibody to RBD: baseline negative placebo arm by sex assigned at birth (version 1)




Figure 3.145: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by sex assigned at birth (version 1)




Figure 3.146: lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by sex assigned at birth (version 1)




Figure 3.147: lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by sex assigned at birth (version 1)




Figure 3.148: lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by sex assigned at birth (version 1)




Figure 3.149: lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by sex assigned at birth (version 1)




Figure 3.150: violinplots of Binding Antibody to Spike: baseline negative placebo arm by sex assigned at birth (version 1)




Figure 3.151: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by sex assigned at birth (version 1)




Figure 3.152: violinplots of Binding Antibody to RBD: baseline negative placebo arm by sex assigned at birth (version 1)




Figure 3.153: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by sex assigned at birth (version 1)




Figure 3.154: violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by sex assigned at birth (version 1)




Figure 3.155: violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by sex assigned at birth (version 1)




Figure 3.156: violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by sex assigned at birth (version 1)




Figure 3.157: violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by sex assigned at birth (version 1)




Figure 3.158: lineplots of Binding Antibody to Spike: baseline negative placebo arm by sex assigned at birth (version 2)




Figure 3.159: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by sex assigned at birth (version 2)




Figure 3.160: lineplots of Binding Antibody to RBD: baseline negative placebo arm by sex assigned at birth (version 2)




Figure 3.161: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by sex assigned at birth (version 2)




Figure 3.162: lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by sex assigned at birth (version 2)




Figure 3.163: lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by sex assigned at birth (version 2)




Figure 3.164: lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by sex assigned at birth (version 2)




Figure 3.165: lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by sex assigned at birth (version 2)




Figure 3.166: violinplots of Binding Antibody to Spike: baseline negative placebo arm by sex assigned at birth (version 2)




Figure 3.167: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by sex assigned at birth (version 2)




Figure 3.168: violinplots of Binding Antibody to RBD: baseline negative placebo arm by sex assigned at birth (version 2)




Figure 3.169: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by sex assigned at birth (version 2)




Figure 3.170: violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by sex assigned at birth (version 2)




Figure 3.171: violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by sex assigned at birth (version 2)




Figure 3.172: violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by sex assigned at birth (version 2)




Figure 3.173: violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by sex assigned at birth (version 2)




Figure 3.174: lineplots of Binding Antibody to Spike: baseline negative placebo arm by race and ethnic group (version 1)




Figure 3.175: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by race and ethnic group (version 1)




Figure 3.176: lineplots of Binding Antibody to RBD: baseline negative placebo arm by race and ethnic group (version 1)




Figure 3.177: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by race and ethnic group (version 1)




Figure 3.178: lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by race and ethnic group (version 1)




Figure 3.179: lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by race and ethnic group (version 1)




Figure 3.180: lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by race and ethnic group (version 1)




Figure 3.181: lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by race and ethnic group (version 1)




Figure 3.182: violinplots of Binding Antibody to Spike: baseline negative placebo arm by race and ethnic group (version 1)




Figure 3.183: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by race and ethnic group (version 1)




Figure 3.184: violinplots of Binding Antibody to RBD: baseline negative placebo arm by race and ethnic group (version 1)




Figure 3.185: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by race and ethnic group (version 1)




Figure 3.186: violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by race and ethnic group (version 1)




Figure 3.187: violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by race and ethnic group (version 1)




Figure 3.188: violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by race and ethnic group (version 1)




Figure 3.189: violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by race and ethnic group (version 1)




Figure 3.190: lineplots of Binding Antibody to Spike: baseline negative placebo arm by race and ethnic group (version 2)




Figure 3.191: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by race and ethnic group (version 2)




Figure 3.192: lineplots of Binding Antibody to RBD: baseline negative placebo arm by race and ethnic group (version 2)




Figure 3.193: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by race and ethnic group (version 2)




Figure 3.194: lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by race and ethnic group (version 2)




Figure 3.195: lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by race and ethnic group (version 2)




Figure 3.196: lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by race and ethnic group (version 2)




Figure 3.197: lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by race and ethnic group (version 2)




Figure 3.198: violinplots of Binding Antibody to Spike: baseline negative placebo arm by race and ethnic group (version 2)




Figure 3.199: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by race and ethnic group (version 2)




Figure 3.200: violinplots of Binding Antibody to RBD: baseline negative placebo arm by race and ethnic group (version 2)




Figure 3.201: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by race and ethnic group (version 2)




Figure 3.202: violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by race and ethnic group (version 2)




Figure 3.203: violinplots of Pseudovirus Neutralization ID₅₀: baseline negative vaccine arm by race and ethnic group (version 2)




Figure 3.204: violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by race and ethnic group (version 2)




Figure 3.205: violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by race and ethnic group (version 2)




Figure 3.206: lineplots of Binding Antibody to Spike: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)




Figure 3.207: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)




Figure 3.208: lineplots of Binding Antibody to RBD: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)




Figure 3.209: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)




Figure 3.210: lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)




Figure 3.211: lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)




Figure 3.212: lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)




Figure 3.213: lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)




Figure 3.214: violinplots of Binding Antibody to Spike: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)




Figure 3.215: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)




Figure 3.216: violinplots of Binding Antibody to RBD: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)




Figure 3.217: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)




Figure 3.218: violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)




Figure 3.219: violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)




Figure 3.220: violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 1)




Figure 3.221: violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 1)




Figure 3.222: lineplots of Binding Antibody to Spike: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)




Figure 3.223: lineplots of Binding Antibody to Spike: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)




Figure 3.224: lineplots of Binding Antibody to RBD: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)




Figure 3.225: lineplots of Binding Antibody to RBD: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)




Figure 3.226: lineplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)




Figure 3.227: lineplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)




Figure 3.228: lineplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)




Figure 3.229: lineplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)




Figure 3.230: violinplots of Binding Antibody to Spike: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)




Figure 3.231: violinplots of Binding Antibody to Spike: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)




Figure 3.232: violinplots of Binding Antibody to RBD: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)




Figure 3.233: violinplots of Binding Antibody to RBD: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)




Figure 3.234: violinplots of Pseudovirus Neutralization ID50: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)




Figure 3.235: violinplots of Pseudovirus Neutralization ID50: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)




Figure 3.236: violinplots of Pseudovirus Neutralization ID80: baseline negative placebo arm by dichotomous classification of race and ethnic group (version 2)




Figure 3.237: violinplots of Pseudovirus Neutralization ID80: baseline negative vaccine arm by dichotomous classification of race and ethnic group (version 2)




Figure 3.238: scatterplots of Binding Antibody to Spike vs Age: baseline negative vaccine arm at day 1




Figure 3.239: scatterplots of Binding Antibody to Spike vs Age: baseline negative vaccine arm at day 29




Figure 3.240: scatterplots of Binding Antibody to Spike vs Age: baseline negative vaccine arm at day 57




Figure 3.241: scatterplots of Binding Antibody to RBD vs Age: baseline negative vaccine arm at day 1




Figure 3.242: scatterplots of Binding Antibody to RBD vs Age: baseline negative vaccine arm at day 29




Figure 3.243: scatterplots of Binding Antibody to RBD vs Age: baseline negative vaccine arm at day 57




Figure 3.244: scatterplots of Pseudovirus Neutralization ID₅₀ vs Age: baseline negative vaccine arm at day 1




Figure 3.245: scatterplots of Pseudovirus Neutralization ID50 vs Age: baseline negative vaccine arm at day 29




Figure 3.246: scatterplots of Pseudovirus Neutralization ID50 vs Age: baseline negative vaccine arm at day 57




Figure 3.247: scatterplots of Pseudovirus Neutralization ID80 vs Age: baseline negative vaccine arm at day 1




Figure 3.248: scatterplots of Pseudovirus Neutralization ID80 vs Age: baseline negative vaccine arm at day 29




Figure 3.249: scatterplots of Pseudovirus Neutralization ID80 vs Age: baseline negative vaccine arm at day 57




Figure 3.250: scatterplots of Binding Antibody to Spike vs Age: by arm at day 1




Figure 3.251: scatterplots of Binding Antibody to Spike vs Age: by arm at day 29




Figure 3.252: scatterplots of Binding Antibody to Spike vs Age: by arm at day 57




Figure 3.253: scatterplots of Binding Antibody to RBD vs Age: by arm at day 1




Figure 3.254: scatterplots of Binding Antibody to RBD vs Age: by arm at day 29




Figure 3.255: scatterplots of Binding Antibody to RBD vs Age: by arm at day 57




Figure 3.256: scatterplots of Pseudovirus Neutralization ID50 vs Age vs Age: by arm at day 1




Figure 3.257: scatterplots of Pseudovirus Neutralization ID50 vs Age vs Age: by arm at day 29




Figure 3.258: scatterplots of Pseudovirus Neutralization ID50 vs Age: by arm at day 57




Figure 3.259: scatterplots of Pseudovirus Neutralization ID80 vs Age: by arm at day 1




Figure 3.260: scatterplots of Pseudovirus Neutralization ID80 vs Age: by arm at day 29




Figure 3.261: scatterplots of Pseudovirus Neutralization ID80 vs Age: by arm at day 57




Figure 3.262: scatterplots of Binding Antibody to Spike vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 1




Figure 3.263: scatterplots of Binding Antibody to Spike vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 29




Figure 3.264: scatterplots of Binding Antibody to Spike vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 57




Figure 3.265: scatterplots of Binding Antibody to RBD vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 1




Figure 3.266: scatterplots of Binding Antibody to RBD vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 29




Figure 3.267: scatterplots of Binding Antibody to RBD vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 57




Figure 3.268: scatterplots of Pseudovirus Neutralization ID₅₀ vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 1




Figure 3.269: scatterplots of Pseudovirus Neutralization ID₅₀ vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 29




Figure 3.270: scatterplots of Pseudovirus Neutralization ID50 vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 57




Figure 3.271: scatterplots of Pseudovirus Neutralization ID80 vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 1




Figure 3.272: scatterplots of Psuedovirus Neutralization ID80 vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 29




Figure 3.273: scatterplots of Pseudovirus Neutralization ID80 vs Days Since the Day 29 Visit: baseline negative vaccine arm at day 57




Figure 3.274: scatterplots of Binding Antibody to Spike vs Days Since the Day 29 Visit: by arm at day 1




Figure 3.275: scatterplots of Binding Antibody to Spike vs Days Since the Day 29 Visit: by arm at day 29




Figure 3.276: scatterplots of Binding Antibody to Spike vs Days Since the Day 29 Visit: by arm at day 57




Figure 3.277: scatterplots of Binding Antibody to RBD vs Days Since the Day 29 Visit: by arm at day 1




Figure 3.278: scatterplots of Binding Antibody to RBD vs Days Since the Day 29 Visit: by arm at day 29




Figure 3.279: scatterplots of Binding Antibody to RBD vs Days Since the Day 29 Visit: by arm at day 57




Figure 3.280: scatterplots of Pseudovirus Neutralization ID50 vs Days Since the Day 29 Visit vs Days Since the Day 29 Visit: by arm at day 1




Figure 3.281: scatterplots of Pseudovirus Neutralization ID50 vs Days Since the Day 29 Visit vs Days Since the Day 29 Visit: by arm at day 29




Figure 3.282: scatterplots of Pseudovirus Neutralization ID50 vs Days Since the Day 29 Visit: by arm at day 57




Figure 3.283: scatterplots of Pseudovirus Neutralization ID80 vs Days Since the Day 29 Visit: by arm at day 1




Figure 3.284: scatterplots of Pseudovirus Neutralization ID80 vs Days Since the Day 29 Visit: by arm at day 29




Figure 3.285: scatterplots of Pseudovirus Neutralization ID80 vs Days Since the Day 29 Visit: by arm at day 57

Chapter 4

Day 57 Univariate CoR: Cox Models of Risk

The main regression model is the Cox proportional hazards model. All plots are made with Cox models fit unless specified otherwise.

4.1 Hazard ratios

Table 4.1: Inference for Day 57 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios per 10-fold increment in the marker*

| MockCOVE Immunologic Marker | No. cases / No. at-risk** | HR per 10-fold incr. Pt. Est. | 95% CI | P-value (2-sided) | q-value *** | FWER |
|--------------------------------|------------------------------|----------------------------------|-------------|----------------------|----------------|------|
| Anti Spike IgG (IU/ml) | 52/11,117 | 0.20 | (0.12-0.36) | <0.001 | N/A | N/A |
| Anti RBD IgG (IU/ml) | 52/11,117 | 0.43 | (0.25-0.74) | 0.003 | N/A | N/A |
| Pseudovirus-nAb ID50 | 52/11,117 | 0.32 | (0.17-0.60) | <0.001 | N/A | N/A |
| Pseudovirus-nAb ID80 | 52/11,117 | 0.35 | (0.19-0.64) | <0.001 | N/A | N/A |

*Baseline covariates adjusted for: baseline risk score, at risk or not, community of color or not. Maximum failure event time 164 days.

**No. at-risk = number of per-protocol baseline negative vaccine recipients at-risk for COVID; no. cases = number of this cohort with an observed COVID endpoints starting 7 days post Day 57 visit.

***q-value and FWER (family-wide error rate) are computed over the set of p-values both for quantitative markers and categorical markers (excluding ID80) using the Westfall and Young permutation method (5 replicates).

Table 4.2: Inference for Day 57 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios for Middle vs. Upper tertile vs. Lower tertile*

| MockCOVE Immunologic Marker | Tertile | No. cases / No. at-risk** | Attack rate | Pt. Est. | Haz. Ratio 95% CI | P-value (2-sided) | Overall P- value*** | Overall q- value † | Overall FWER |
|--------------------------------|---------|------------------------------|----------------|----------|----------------------|----------------------|------------------------|-----------------------|-----------------|
| Anti Spike IgG (IU/ml) | Lower | 27/4,235 | 0.0064 | 1 | N/A | N/A | <0.001 | N/A | N/A |
| | Middle | 18/4,243 | 0.0042 | 0.30 | (0.16-0.59) | <0.001 | | | |
| | Upper | 7/2,638 | 0.0027 | 0.08 | (0.03-0.21) | <0.001 | | | |
| Anti RBD IgG (IU/ml) | Lower | 24/4,242 | 0.0057 | 1 | N/A | N/A | 0.003 | N/A | N/A |
| | Middle | 14/4,209 | 0.0033 | 0.32 | (0.15-0.71) | 0.005 | | | |
| | Upper | 14/2,666 | 0.0053 | 0.29 | (0.13-0.64) | 0.002 | | | |
| Pseudovirus-nAb ID50 | Lower | 18/3,697 | 0.0049 | 1 | N/A | N/A | 0.036 | N/A | N/A |
| | Middle | 20/3,701 | 0.0054 | 0.80 | (0.39-1.65) | 0.553 | | | |
| | Upper | 14/3,719 | 0.0038 | 0.36 | (0.16-0.83) | 0.015 | | | |
| Pseudovirus-nAb ID80 | Lower | 22/3,724 | 0.0059 | 1 | N/A | N/A | 0.009 | N/A | N/A |
| | Middle | 20/3,707 | 0.0054 | 0.67 | (0.35-1.28) | 0.223 | | | |
| | Upper | 10/3,687 | 0.0027 | 0.29 | (0.13-0.64) | 0.002 | | | |
| Placebo | | 1010/11,217 | 0.0900 | | | | | | |

*Baseline covariates adjusted for: baseline risk score, at risk or not, community of color or not. Maximum failure event time 164 days. Cutpoints: Anti Spike IgG (IU/ml) [3.34, 4.01], Anti RBD IgG (IU/ml) [3.48, 4.21], Pseudovirus-nAb ID50 [2.37, 2.86], Pseudovirus-nAb ID80 [2.58, 2.96], all on the log10 scale.

**No. at-risk = number of per-protocol baseline negative vaccine recipients at-risk for COVID at 7 days post Day 57 visit; no. cases = number of this cohort with an observed COVID endpoints.

***Generalized Wald-test p-value of the null hypothesis that the hazard rate is constant across the Lower, Middle, and Upper tertile groups.

† q-value and FWER (family-wide error rate) are computed over the set of p-values both for quantitative markers and categorical markers (excluding ID80) using the Westfall and Young permutation method (5 replicates).




Figure 4.1: Forest plots of hazard ratios per 10-fold increase in the marker among baseline negative vaccine recipients and subgroups with 95% point-wise confidence intervals.

Binding Antibody to Spike: Day 57




Figure 4.2: Forest plots of hazard ratios per 10-fold increase in the Day 57 binding Ab to spike markers among baseline negative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals.

Binding Antibody to RBD: Day 57




Figure 4.3: Forest plots of hazard ratios per 10-fold increase in the Day 57 binding Ab to RBD markers among baseline negative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals.




Figure 4.4: Forest plots of hazard ratios per 10-fold increase in the Day 57 pseudo neut ID50 markers among baseline negative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals.




Figure 4.5: Forest plots of hazard ratios per 10-fold increase in the Day 57 pseudo neut ID80 markers among baseline negative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals.

4.2 Marginalized risk and controlled vaccine efficacy plots




Figure 4.6: Marginalized cumulative risk by Day 164 as functions of Day 57 markers ($=s$) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (5 replicates). The horizontal lines indicate the overall cumulative risk of the placebo and vaccine arms by Day 164 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3, 1.6, 2.4, 15 for bAb Spike, bAb RBD, PsV nAb ID50, PsV nAb ID80, respectively.




Figure 4.7: Controlled VE with sensitivity analysis as functions of Day 57 markers (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (5 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3, 1.6, 2.4, 15 for bAb Spike, bAb RBD, PsV nAb ID50, PsV nAb ID80, respectively.




Figure 4.8: Marginalized cumulative risk by Day 164 as functions of Day 57 markers above a threshold ($\geq s$) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (at least 5 cases are required, 5 replicates). The horizontal lines indicate the overall cumulative risk of the vaccine arm by Day 164 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. $l_{od} = 0.3, 1.6, 2.4, 15$ for bAb Spike, bAb RBD, PsV nAb ID50, PsV nAb ID80, respectively.




Figure 4.9: Controlled VE as functions of Day 57 markers ($\geq s$) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (5 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3, 1.6, 2.4, 15 for bAb Spike, bAb RBD, PsV nAb ID50, PsV nAb ID80, respectively.




Figure 4.10: Marginalized cumulative incidence rate curves for trichotomized Day 57 markers among baseline negative vaccine recipients. The gray line is the overall cumulative incidence rate curve in the placebo arm.

Chapter 5

Day 29 Univariate CoR: Cox Models of Risk

The main regression model is the Cox proportional hazards model. All plots are made with Cox models fit unless specified otherwise.

5.1 Hazard ratios

Table 5.1: Inference for Day 29 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios per 10-fold increment in the marker*

| MockCOVE Immunologic Marker | No. cases / No. at-risk** | HR per 10-fold incr. Pt. Est. | 95% CI | P-value (2-sided) | q-value *** | FWER |
|--------------------------------|------------------------------|----------------------------------|-------------|----------------------|----------------|------|
| Anti Spike IgG (IU/ml) | 60/11,157 | 0.31 | (0.17-0.54) | <0.001 | N/A | N/A |
| Anti RBD IgG (IU/ml) | 60/11,157 | 0.50 | (0.30-0.85) | 0.010 | N/A | N/A |
| Pseudovirus-nAb ID50 | 60/11,157 | 0.43 | (0.22-0.86) | 0.016 | N/A | N/A |
| Pseudovirus-nAb ID80 | 60/11,157 | 0.35 | (0.18-0.68) | 0.002 | N/A | N/A |

*Baseline covariates adjusted for: baseline risk score, at risk or not, community of color or not. Maximum failure event time 192 days.

**No. at-risk = number of per-protocol baseline negative vaccine recipients at-risk for COVID; no. cases = number of this cohort with an observed COVID endpoints starting 7 days post Day 29 visit.

***q-value and FWER (family-wide error rate) are computed over the set of p-values both for quantitative markers and categorical markers (excluding ID80) using the Westfall and Young permutation method (5 replicates).

Table 5.2: Inference for Day 29 antibody marker covariate-adjusted correlates of risk of COVID in the vaccine group: Hazard ratios for Middle vs. Upper tertile vs. Lower tertile*

| MockCOVE Immunologic Marker | Tertile | No. cases / No. at-risk** | Attack rate | Haz. Ratio Pt. Est. | 95% CI | P-value (2-sided) | Overall P- value*** | Overall q- value † | Overall FWER |
|--------------------------------|---------|------------------------------|----------------|------------------------|-------------|----------------------|------------------------|-----------------------|-----------------|
| Anti Spike IgG (IU/ml) | Lower | 20/3,702 | 0.0054 | 1 | N/A | N/A | 0.004 | N/A | N/A |
| | Middle | 19/3,705 | 0.0051 | 0.57 | (0.28-1.16) | 0.121 | | | |
| | Upper | 20/3,750 | 0.0053 | 0.26 | (0.11-0.58) | <0.001 | | | |
| Anti RBD IgG (IU/ml) | Lower | 26/3,722 | 0.0070 | 1 | N/A | N/A | 0.001 | N/A | N/A |
| | Middle | 13/3,740 | 0.0035 | 0.33 | (0.16-0.67) | 0.002 | | | |
| | Upper | 20/3,695 | 0.0054 | 0.29 | (0.14-0.61) | 0.001 | | | |
| Pseudovirus-nAb ID50 | Lower | 20/3,690 | 0.0054 | 1 | N/A | N/A | 0.053 | N/A | N/A |
| | Middle | 23/3,749 | 0.0061 | 0.97 | (0.50-1.89) | 0.933 | | | |
| | Upper | 16/3,718 | 0.0043 | 0.45 | (0.21-0.96) | 0.038 | | | |
| Pseudovirus-nAb ID80 | Lower | 20/3,754 | 0.0053 | 1 | N/A | N/A | 0.028 | N/A | N/A |
| | Middle | 26/3,719 | 0.0070 | 1.15 | (0.61-2.17) | 0.674 | | | |
| | Upper | 13/3,685 | 0.0035 | 0.45 | (0.21-0.96) | 0.038 | | | |
| Placebo | | 1169/11,426 | 0.1023 | | | | | | |

*Baseline covariates adjusted for: baseline risk score, at risk or not, community of color or not. Maximum failure event time 192 days. Cutpoints: Anti Spike IgG (IU/ml) [2.14, 2.65], Anti RBD IgG (IU/ml) [2.37, 2.98], Pseudovirus-nAb ID50 [1.07, 1.45], Pseudovirus-nAb ID80 [1.26, 1.61], all on the log10 scale.

**No. at-risk = number of per-protocol baseline negative vaccine recipients at-risk for COVID at 7 days post Day 29 visit; no. cases = number of this cohort with an observed COVID endpoints.

***Generalized Wald-test p-value of the null hypothesis that the hazard rate is constant across the Lower, Middle, and Upper tertile groups.

† q-value and FWER (family-wide error rate) are computed over the set of p-values both for quantitative markers and categorical markers (excluding ID80) using the Westfall and Young permutation method (5 replicates).




Figure 5.1: Forest plots of hazard ratios per 10-fold increase in the marker among baseline negative vaccine recipients and subgroups with 95% point-wise confidence intervals.

Binding Antibody to Spike: Day 29




Figure 5.2: Forest plots of hazard ratios per 10-fold increase in the Day 29 binding Ab to spike markers among baseline negative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals.

Binding Antibody to RBD: Day 29




Figure 5.3: Forest plots of hazard ratios per 10-fold increase in the Day 29 binding Ab to RBD markers among baseline negative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals.

PsV Neutralization 50% Titer: Day 29




Figure 5.4: Forest plots of hazard ratios per 10-fold increase in the Day 29 pseudo neut ID50 markers among baseline negative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals.

PsV Neutralization 80% Titer: Day 29




Figure 5.5: Forest plots of hazard ratios per 10-fold increase in the Day 29 pseudo neut ID80 markers among baseline negative vaccine recipients (top row) and eight subpopulations (row 2-9) with 95% point-wise confidence intervals.

5.2 Marginalized risk and controlled vaccine efficacy plots




Figure 5.6: Marginalized cumulative risk by Day 192 as functions of Day 29 markers (=s) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (5 replicates). The horizontal lines indicate the overall cumulative risk of the placebo and vaccine arms by Day 192 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3, 1.6, 2.4, 15 for bAb Spike, bAb RBD, PsV nAb ID50, PsV nAb ID80, respectively.




Figure 5.7: Controlled VE with sensitivity analysis as functions of Day 29 markers ($=s$) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (5 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. $lod = 0.3, 1.6, 2.4, 15$ for bAb Spike, bAb RBD, PsV nAb ID50, PsV nAb ID80, respectively.




Figure 5.8: Marginalized cumulative risk by Day 192 as functions of Day 29 markers above a threshold ($\geq s$) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (at least 5 cases are required, 5 replicates). The horizontal lines indicate the overall cumulative risk of the vaccine arm by Day 192 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. $l_{od} = 0.3, 1.6, 2.4, 15$ for bAb Spike, bAb RBD, PsV nAb ID50, PsV nAb ID80, respectively.




Figure 5.9: Controlled VE as functions of Day 29 markers ($\geq s$) among baseline negative vaccine recipients with 95% bootstrap point-wise confidence bands (5 replicates). Histograms of the immunological markers in the vaccine arm are overlaid. $l_{od} = 0.3, 1.6, 2.4, 15$ for bAb Spike, bAb RBD, PsV nAb ID50, PsV nAb ID80, respectively.




Figure 5.10: Marginalized cumulative incidence rate curves for trichotomized Day 29 markers among baseline negative vaccine recipients. The gray line is the overall cumulative incidence rate curve in the placebo arm.

Chapter 6

Univariate CoR: Nonparametric Threshold Modeling ($>= s$)

An extension of the unadjusted nonparametric threshold-searching approach developed in Donovan, Hudgens, and Gilbert (2019), the covariate-adjusted TMLE-based approach developed by van der Laan, Zhang, Gilbert (submitted) is used to estimate the so-called threshold-response function $E_X[E[Y | S \geq s, X, A = 1] | A = 1]$ for a range of thresholds s . Here, X is a set of baseline characteristics, $A = 1$ represents the vaccine group, S is the biomarker/immune-response/correlate of interest, and Y is the indicator of COVID disease before some time point t_f . This parameter can be viewed as a causal/covariate-adjusted version of the parameter $P(Y = 1 | S \geq s, A = 1)$. Intuitively, the threshold-response at a given threshold is the expected probability of obtaining COVID disease if one experiences a marker/immune-response value above that threshold. The threshold-response function is estimated for each of the four Day 57 antibody markers, in each case adjusting for the baseline covariates: baseline risk score, high risk indicator, and underrepresented minority status. A parametric learner, selected via cross-validation, is used for the covariate adjustment. A number of plots and tables are reported:

1. A plot and table with risk estimates and point-wise 95% confidence intervals
2. A plot and table with risk estimates and simultaneous 95% confidence bands
3. Monotone-corrected versions of 1 and 2.

A reverse cumulative distribution function curve estimated by the IPW NPMLE of the marker values is superimposed on the threshold-response plots and a dashed red line is added to mark the threshold value after which no more events are observed.

6.1 Plots and Tables with estimates and pointwise confidence interval for Day 57

MOCK

6.1.1 Day 57 Spike protein binding antibody




Figure 6.1: Adjusted threshold-response function for a range of thresholds of the Day 57 Spike protein binding antibody levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed.

Table 6.1: Table of risk estimates for a range of thresholds of Day 57 Spike protein binding antibody levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.316 | $2.07 * 10^1$ | 0.00468 | 0.00334 | 0.00602 |
| 2.657 | $4.54 * 10^2$ | 0.00420 | 0.00291 | 0.00548 |
| 2.951 | $8.93 * 10^2$ | 0.00344 | 0.00224 | 0.00464 |
| 3.221 | $1.66 * 10^3$ | 0.00270 | 0.00164 | 0.00375 |
| 3.394 | $2.48 * 10^3$ | 0.00256 | 0.00150 | 0.00361 |
| 3.544 | $3.50 * 10^3$ | 0.00201 | 0.00102 | 0.00299 |
| 3.658 | $4.55 * 10^3$ | 0.00159 | 0.00070 | 0.00249 |
| 3.841 | $6.93 * 10^3$ | 0.00131 | 0.00047 | 0.00215 |
| 3.973 | $9.40 * 10^3$ | 0.00105 | 0.00025 | 0.00184 |
| 4.007 | $1.02 * 10^4$ | 0.00121 | 0.00027 | 0.00215 |

6.1.2 Day 57 RBD binding antibody




Figure 6.2: Adjusted threshold-response function for a range of thresholds of the Day 57 RBD binding antibody levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed.

Table 6.2: Table of risk estimates for a range of thresholds of Day 57 RBD binding antibody levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.073 | $1.18 * 10^1$ | 0.00468 | 0.00334 | 0.00602 |
| 2.715 | $5.19 * 10^2$ | 0.00440 | 0.00306 | 0.00573 |
| 3.022 | $1.05 * 10^3$ | 0.00406 | 0.00273 | 0.00538 |
| 3.338 | $2.18 * 10^3$ | 0.00337 | 0.00208 | 0.00466 |
| 3.514 | $3.27 * 10^3$ | 0.00306 | 0.00180 | 0.00431 |
| 3.657 | $4.54 * 10^3$ | 0.00325 | 0.00183 | 0.00467 |
| 3.797 | $6.27 * 10^3$ | 0.00324 | 0.00176 | 0.00472 |
| 3.986 | $9.68 * 10^3$ | 0.00367 | 0.00186 | 0.00549 |
| 4.125 | $1.33 * 10^4$ | 0.00368 | 0.00170 | 0.00566 |
| 4.211 | $1.63 * 10^4$ | 0.00309 | 0.00131 | 0.00488 |

6.1.3 Day 57 Pseudo virus-neutralizing antibody (50% titer)




Figure 6.3: Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed.

Table 6.3: Table of risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.135 | $1.36 * 10^1$ | 0.00468 | 0.00334 | 0.00602 |
| 2.055 | $1.14 * 10^2$ | 0.00407 | 0.00276 | 0.00538 |
| 2.281 | $1.91 * 10^2$ | 0.00415 | 0.00272 | 0.00558 |
| 2.519 | $3.30 * 10^2$ | 0.00349 | 0.00207 | 0.00490 |
| 2.657 | $4.54 * 10^2$ | 0.00237 | 0.00112 | 0.00362 |
| 2.828 | $6.73 * 10^2$ | 0.00283 | 0.00125 | 0.00440 |
| 2.959 | $9.10 * 10^2$ | 0.00287 | 0.00095 | 0.00480 |
| 3.174 | $1.49 * 10^3$ | 0.00217 | 0.00029 | 0.00406 |
| 3.387 | $2.44 * 10^3$ | 0.00125 | 0.00000 | 0.00329 |
| 4.038 | $1.09 * 10^4$ | 0.00000 | 0.00000 | NA |

6.1.4 Day 57 Pseudo virus-neutralizing antibody (80% titer)




Figure 6.4: Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed.

Table 6.4: Table of risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.403 | $2.53 * 10^1$ | 0.00468 | 0.00334 | 0.00602 |
| 2.220 | $1.66 * 10^2$ | 0.00420 | 0.00286 | 0.00553 |
| 2.455 | $2.85 * 10^2$ | 0.00363 | 0.00234 | 0.00493 |
| 2.644 | $4.41 * 10^2$ | 0.00380 | 0.00232 | 0.00528 |
| 2.764 | $5.81 * 10^2$ | 0.00300 | 0.00164 | 0.00437 |
| 2.874 | $7.48 * 10^2$ | 0.00280 | 0.00129 | 0.00431 |
| 2.981 | $9.57 * 10^2$ | 0.00238 | 0.00078 | 0.00398 |
| 3.162 | $1.45 * 10^3$ | 0.00167 | 0.00000 | 0.00342 |
| 3.371 | $2.35 * 10^3$ | 0.00064 | 0.00000 | 0.00194 |
| 4.187 | $1.54 * 10^4$ | 0.00000 | 0.00000 | NA |

6.2 Plots and Tables with estimates and pointwise confidence intervals for Day 29

MOCK

6.2.1 Day 29 Spike protein antibody




Figure 6.5: Adjusted threshold-response function for a range of thresholds of the Day 29 Spike protein antibody levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed.

Table 6.5: Table of risk estimates for a range of thresholds of Day 29 Spike protein antibody levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 0.613 | $4.10 * 10^0$ | 0.00538 | 0.00392 | 0.00683 |
| 1.805 | $6.38 * 10^1$ | 0.00444 | 0.00308 | 0.00581 |
| 2.081 | $1.21 * 10^2$ | 0.00445 | 0.00299 | 0.00590 |
| 2.351 | $2.24 * 10^2$ | 0.00331 | 0.00202 | 0.00459 |
| 2.522 | $3.33 * 10^2$ | 0.00303 | 0.00167 | 0.00440 |
| 2.677 | $4.75 * 10^2$ | 0.00347 | 0.00174 | 0.00521 |
| 2.841 | $6.93 * 10^2$ | 0.00375 | 0.00171 | 0.00579 |
| 3.112 | $1.29 * 10^3$ | 0.00179 | 0.00025 | 0.00333 |
| 3.348 | $2.23 * 10^3$ | 0.00030 | 0.00000 | 0.00093 |
| 4.007 | $1.02 * 10^4$ | 0.00000 | 0.00000 | NA |

6.2.2 Day 29 RBD binding antibody




Figure 6.6: Adjusted threshold-response function for a range of thresholds of the Day 29 RBD binding antibody levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed.

Table 6.6: Table of risk estimates for a range of thresholds of Day 29 RBD binding antibody levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 0.834 | $6.82 * 10^0$ | 0.00538 | 0.00392 | 0.00683 |
| 1.892 | $7.80 * 10^1$ | 0.00493 | 0.00347 | 0.00638 |
| 2.273 | $1.87 * 10^2$ | 0.00434 | 0.00289 | 0.00579 |
| 2.575 | $3.76 * 10^2$ | 0.00379 | 0.00228 | 0.00531 |
| 2.780 | $6.03 * 10^2$ | 0.00401 | 0.00225 | 0.00576 |
| 2.960 | $9.12 * 10^2$ | 0.00454 | 0.00231 | 0.00678 |
| 3.144 | $1.39 * 10^3$ | 0.00454 | 0.00218 | 0.00691 |
| 3.461 | $2.89 * 10^3$ | 0.00405 | 0.00108 | 0.00702 |
| 3.736 | $5.45 * 10^3$ | 0.00917 | 0.00184 | 0.01650 |
| 4.211 | $1.63 * 10^4$ | 0.00434 | 0.00000 | 0.01454 |

6.2.3 Day 29 Pseudo virus-neutralizing antibody (50% titer)




Figure 6.7: Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed.

Table 6.7: Table of risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 0.083 | $1.21 * 10^0$ | 0.00538 | 0.00392 | 0.00683 |
| 0.779 | $6.01 * 10^0$ | 0.00487 | 0.00342 | 0.00632 |
| 0.988 | $9.73 * 10^0$ | 0.00458 | 0.00307 | 0.00608 |
| 1.147 | $1.40 * 10^1$ | 0.00470 | 0.00297 | 0.00643 |
| 1.271 | $1.87 * 10^1$ | 0.00411 | 0.00239 | 0.00582 |
| 1.382 | $2.41 * 10^1$ | 0.00327 | 0.00158 | 0.00496 |
| 1.481 | $3.03 * 10^1$ | 0.00294 | 0.00121 | 0.00467 |
| 1.656 | $4.53 * 10^1$ | 0.00357 | 0.00104 | 0.00610 |
| 1.852 | $7.11 * 10^1$ | 0.00600 | 0.00068 | 0.01132 |
| 2.879 | $7.57 * 10^2$ | 0.00000 | 0.00000 | NA |

6.2.4 Day 29 Pseudo virus-neutralizing antibody (80% titer)




Figure 6.8: Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed.

Table 6.8: Table of risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 0.876 | $7.52 * 10^0$ | 0.00538 | 0.00392 | 0.00683 |
| 1.260 | $1.82 * 10^1$ | 0.00494 | 0.00328 | 0.00660 |
| 1.339 | $2.18 * 10^1$ | 0.00474 | 0.00302 | 0.00646 |
| 1.440 | $2.75 * 10^1$ | 0.00381 | 0.00212 | 0.00549 |
| 1.541 | $3.48 * 10^1$ | 0.00267 | 0.00117 | 0.00417 |
| 1.610 | $4.07 * 10^1$ | 0.00293 | 0.00123 | 0.00463 |
| 1.707 | $5.09 * 10^1$ | 0.00246 | 0.00061 | 0.00432 |
| 1.839 | $6.90 * 10^1$ | 0.00205 | 0.00000 | 0.00431 |
| 1.956 | $9.04 * 10^1$ | 0.00049 | 0.00000 | 0.00153 |
| 2.719 | $5.24 * 10^2$ | 0.00000 | 0.00000 | NA |

6.3 Plots and Tables with estimates and pointwise confidence interval for Day 57 (monotone-corrected)

MOCK

6.3.1 Day 57 Spike protein binding antibody




Figure 6.9: Adjusted threshold-response function for a range of thresholds of the Day 57 Spike protein binding antibody levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 6.9: Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Spike protein binding antibody levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.316 | $2.07 * 10^1$ | 0.00468 | 0.00334 | 0.00602 |
| 2.657 | $4.54 * 10^2$ | 0.00420 | 0.00291 | 0.00548 |
| 2.951 | $8.93 * 10^2$ | 0.00344 | 0.00224 | 0.00464 |
| 3.221 | $1.66 * 10^3$ | 0.00270 | 0.00164 | 0.00375 |
| 3.394 | $2.48 * 10^3$ | 0.00256 | 0.00150 | 0.00361 |
| 3.544 | $3.50 * 10^3$ | 0.00201 | 0.00102 | 0.00299 |
| 3.658 | $4.55 * 10^3$ | 0.00162 | 0.00073 | 0.00252 |
| 3.841 | $6.93 * 10^3$ | 0.00131 | 0.00047 | 0.00215 |
| 3.973 | $9.40 * 10^3$ | 0.00115 | 0.00035 | 0.00195 |
| 4.007 | $1.02 * 10^4$ | 0.00115 | 0.00021 | 0.00209 |

6.3.2 Day 57 RBD binding antibody




Figure 6.10: Adjusted threshold-response function for a range of thresholds of the Day 57 RBD binding antibody levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 6.10: Table of monotone-corrected risk estimates for a range of thresholds of Day 57 RBD binding antibody levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.073 | $1.18 * 10^1$ | 0.00468 | 0.00334 | 0.00602 |
| 2.715 | $5.19 * 10^2$ | 0.00440 | 0.00306 | 0.00573 |
| 3.022 | $1.05 * 10^3$ | 0.00406 | 0.00273 | 0.00538 |
| 3.338 | $2.18 * 10^3$ | 0.00338 | 0.00209 | 0.00467 |
| 3.514 | $3.27 * 10^3$ | 0.00338 | 0.00213 | 0.00463 |
| 3.657 | $4.54 * 10^3$ | 0.00338 | 0.00196 | 0.00480 |
| 3.797 | $6.27 * 10^3$ | 0.00338 | 0.00190 | 0.00486 |
| 3.986 | $9.68 * 10^3$ | 0.00338 | 0.00157 | 0.00519 |
| 4.125 | $1.33 * 10^4$ | 0.00338 | 0.00140 | 0.00536 |
| 4.211 | $1.63 * 10^4$ | 0.00309 | 0.00131 | 0.00488 |

6.3.3 Day 57 Pseudo virus-neutralizing antibody (50% titer)




Figure 6.11: Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 6.11: Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|--------------------|---------------|---------|----------|
| 1.135 | 1.36×10^1 | 0.00468 | 0.00334 | 0.00602 |
| 2.055 | 1.14×10^2 | 0.00412 | 0.00281 | 0.00543 |
| 2.281 | 1.91×10^2 | 0.00412 | 0.00269 | 0.00554 |
| 2.519 | 3.30×10^2 | 0.00349 | 0.00207 | 0.00490 |
| 2.657 | 4.54×10^2 | 0.00267 | 0.00141 | 0.00392 |
| 2.828 | 6.73×10^2 | 0.00267 | 0.00109 | 0.00424 |
| 2.959 | 9.10×10^2 | 0.00267 | 0.00074 | 0.00459 |
| 3.174 | 1.49×10^3 | 0.00217 | 0.00029 | 0.00406 |
| 3.387 | 2.44×10^3 | 0.00125 | 0.00000 | 0.00329 |
| 4.038 | 1.09×10^4 | 0.00000 | 0.00000 | NA |

6.3.4 Day 57 Pseudo virus-neutralizing antibody (80% titer)




Figure 6.12: Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 6.12: Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.403 | $2.53 * 10^1$ | 0.00469 | 0.00335 | 0.00603 |
| 2.220 | $1.66 * 10^2$ | 0.00420 | 0.00286 | 0.00553 |
| 2.455 | $2.85 * 10^2$ | 0.00367 | 0.00238 | 0.00497 |
| 2.644 | $4.41 * 10^2$ | 0.00367 | 0.00219 | 0.00515 |
| 2.764 | $5.81 * 10^2$ | 0.00300 | 0.00164 | 0.00437 |
| 2.874 | $7.48 * 10^2$ | 0.00280 | 0.00129 | 0.00431 |
| 2.981 | $9.57 * 10^2$ | 0.00238 | 0.00078 | 0.00398 |
| 3.162 | $1.45 * 10^3$ | 0.00190 | 0.00015 | 0.00365 |
| 3.371 | $2.35 * 10^3$ | 0.00085 | 0.00000 | 0.00216 |
| 4.187 | $1.54 * 10^4$ | 0.00000 | 0.00000 | NA |

6.4 Plots and Tables with estimates and pointwise confidence intervals for Day 29 (monotone-corrected)

MOCK

6.4.1 Day 29 Spike protein antibody




Figure 6.13: Adjusted threshold-response function for a range of thresholds of the Day 29 Spike protein antibody levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 6.13: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Spike protein antibody levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|--------------------|---------------|---------|----------|
| 0.613 | 4.10×10^0 | 0.00538 | 0.00392 | 0.00683 |
| 1.805 | 6.38×10^1 | 0.00450 | 0.00314 | 0.00587 |
| 2.081 | 1.21×10^2 | 0.00445 | 0.00299 | 0.00590 |
| 2.351 | 2.24×10^2 | 0.00343 | 0.00214 | 0.00472 |
| 2.522 | 3.33×10^2 | 0.00343 | 0.00206 | 0.00480 |
| 2.677 | 4.75×10^2 | 0.00343 | 0.00169 | 0.00517 |
| 2.841 | 6.93×10^2 | 0.00343 | 0.00139 | 0.00547 |
| 3.112 | 1.29×10^3 | 0.00179 | 0.00025 | 0.00333 |
| 3.348 | 2.23×10^3 | 0.00035 | 0.00000 | 0.00099 |
| 4.007 | 1.02×10^4 | 0.00000 | 0.00000 | NA |

6.4.2 Day 29 RBD binding antibody




Figure 6.14: Adjusted threshold-response function for a range of thresholds of the Day 29 RBD binding antibody levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 6.14: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 RBD binding antibody levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 0.834 | $6.82 * 10^0$ | 0.00538 | 0.00392 | 0.00683 |
| 1.892 | $7.80 * 10^1$ | 0.00493 | 0.00347 | 0.00638 |
| 2.273 | $1.87 * 10^2$ | 0.00458 | 0.00313 | 0.00603 |
| 2.575 | $3.76 * 10^2$ | 0.00458 | 0.00306 | 0.00609 |
| 2.780 | $6.03 * 10^2$ | 0.00458 | 0.00282 | 0.00633 |
| 2.960 | $9.12 * 10^2$ | 0.00458 | 0.00234 | 0.00681 |
| 3.144 | $1.39 * 10^3$ | 0.00458 | 0.00221 | 0.00694 |
| 3.461 | $2.89 * 10^3$ | 0.00458 | 0.00161 | 0.00755 |
| 3.736 | $5.45 * 10^3$ | 0.00458 | 0.00000 | 0.01191 |
| 4.211 | $1.63 * 10^4$ | 0.00429 | 0.00000 | 0.01449 |

6.4.3 Day 29 Pseudo virus-neutralizing antibody (50% titer)




Figure 6.15: Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 6.15: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|--------------------|---------------|---------|----------|
| 0.083 | 1.21×10^0 | 0.00538 | 0.00392 | 0.00683 |
| 0.779 | 6.01×10^0 | 0.00487 | 0.00342 | 0.00632 |
| 0.988 | 9.73×10^0 | 0.00478 | 0.00327 | 0.00628 |
| 1.147 | 1.40×10^1 | 0.00474 | 0.00302 | 0.00647 |
| 1.271 | 1.87×10^1 | 0.00418 | 0.00246 | 0.00589 |
| 1.382 | 2.41×10^1 | 0.00418 | 0.00249 | 0.00587 |
| 1.481 | 3.03×10^1 | 0.00418 | 0.00244 | 0.00591 |
| 1.656 | 4.53×10^1 | 0.00418 | 0.00164 | 0.00671 |
| 1.852 | 7.11×10^1 | 0.00418 | 0.00000 | 0.00950 |
| 2.879 | 7.57×10^2 | 0.00000 | 0.00000 | NA |

6.4.4 Day 29 Pseudo virus-neutralizing antibody (80% titer)




Figure 6.16: Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 6.16: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 0.876 | $7.52 * 10^0$ | 0.00538 | 0.00392 | 0.00683 |
| 1.260 | $1.82 * 10^1$ | 0.00489 | 0.00323 | 0.00655 |
| 1.339 | $2.18 * 10^1$ | 0.00474 | 0.00302 | 0.00646 |
| 1.440 | $2.75 * 10^1$ | 0.00389 | 0.00221 | 0.00557 |
| 1.541 | $3.48 * 10^1$ | 0.00276 | 0.00126 | 0.00426 |
| 1.610 | $4.07 * 10^1$ | 0.00276 | 0.00106 | 0.00446 |
| 1.707 | $5.09 * 10^1$ | 0.00246 | 0.00061 | 0.00432 |
| 1.839 | $6.90 * 10^1$ | 0.00205 | 0.00000 | 0.00431 |
| 1.956 | $9.04 * 10^1$ | 0.00047 | 0.00000 | 0.00151 |
| 2.719 | $5.24 * 10^2$ | 0.00000 | 0.00000 | NA |

6.5 Plots and Tables with estimates and simultaneous confidence bands for Day 57

MOCK

6.5.1 Day 57 Spike protein binding antibody




Figure 6.17: Adjusted threshold-response function for a range of thresholds of the Day 57 Spike protein binding antibody levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed.

Table 6.17: Table of risk estimates for a range of thresholds of Day 57 Spike protein binding antibody levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.316 | $2.07 * 10^1$ | 0.00468 | 0.00288 | 0.00648 |
| 2.657 | $4.54 * 10^2$ | 0.00420 | 0.00247 | 0.00593 |
| 2.951 | $8.93 * 10^2$ | 0.00344 | 0.00182 | 0.00505 |
| 3.221 | $1.66 * 10^3$ | 0.00270 | 0.00127 | 0.00412 |
| 3.394 | $2.48 * 10^3$ | 0.00256 | 0.00114 | 0.00397 |
| 3.544 | $3.50 * 10^3$ | 0.00201 | 0.00068 | 0.00333 |
| 3.658 | $4.55 * 10^3$ | 0.00159 | 0.00039 | 0.00280 |
| 3.841 | $6.93 * 10^3$ | 0.00131 | 0.00018 | 0.00244 |
| 3.973 | $9.40 * 10^3$ | 0.00105 | 0.00000 | 0.00212 |
| 4.007 | $1.02 * 10^4$ | 0.00121 | 0.00000 | 0.00247 |

6.5.2 Day 57 RBD binding antibody




Figure 6.18: Adjusted threshold-response function for a range of thresholds of the Day 57 RBD binding antibody levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed.

Table 6.18: Table of risk estimates for a range of thresholds of Day 57 RBD binding antibody levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.073 | $1.18 * 10^1$ | 0.00468 | 0.00293 | 0.00643 |
| 2.715 | $5.19 * 10^2$ | 0.00440 | 0.00266 | 0.00614 |
| 3.022 | $1.05 * 10^3$ | 0.00406 | 0.00233 | 0.00578 |
| 3.338 | $2.18 * 10^3$ | 0.00337 | 0.00168 | 0.00505 |
| 3.514 | $3.27 * 10^3$ | 0.00306 | 0.00142 | 0.00469 |
| 3.657 | $4.54 * 10^3$ | 0.00325 | 0.00140 | 0.00510 |
| 3.797 | $6.27 * 10^3$ | 0.00324 | 0.00131 | 0.00518 |
| 3.986 | $9.68 * 10^3$ | 0.00367 | 0.00131 | 0.00604 |
| 4.125 | $1.33 * 10^4$ | 0.00368 | 0.00109 | 0.00627 |
| 4.211 | $1.63 * 10^4$ | 0.00309 | 0.00076 | 0.00543 |

6.5.3 Day 57 Pseudo virus-neutralizing antibody (50% titer)




Figure 6.19: Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed.

Table 6.19: Table of risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.135 | $1.36 * 10^1$ | 0.00468 | 0.00274 | 0.00662 |
| 2.055 | $1.14 * 10^2$ | 0.00407 | 0.00217 | 0.00596 |
| 2.281 | $1.91 * 10^2$ | 0.00415 | 0.00208 | 0.00622 |
| 2.519 | $3.30 * 10^2$ | 0.00349 | 0.00144 | 0.00554 |
| 2.657 | $4.54 * 10^2$ | 0.00237 | 0.00056 | 0.00419 |
| 2.828 | $6.73 * 10^2$ | 0.00283 | 0.00055 | 0.00511 |
| 2.959 | $9.10 * 10^2$ | 0.00287 | 0.00008 | 0.00566 |
| 3.174 | $1.49 * 10^3$ | 0.00217 | 0.00000 | 0.00490 |
| 3.387 | $2.44 * 10^3$ | 0.00125 | 0.00000 | 0.00420 |
| 4.038 | $1.09 * 10^4$ | 0.00000 | 0.00000 | NA |

6.5.4 Day 57 Pseudo virus-neutralizing antibody (80% titer)




Figure 6.20: Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed.

Table 6.20: Table of risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.403 | $2.53 * 10^1$ | 0.00468 | 0.00277 | 0.00659 |
| 2.220 | $1.66 * 10^2$ | 0.00420 | 0.00230 | 0.00610 |
| 2.455 | $2.85 * 10^2$ | 0.00363 | 0.00179 | 0.00548 |
| 2.644 | $4.41 * 10^2$ | 0.00380 | 0.00169 | 0.00591 |
| 2.764 | $5.81 * 10^2$ | 0.00300 | 0.00106 | 0.00495 |
| 2.874 | $7.48 * 10^2$ | 0.00280 | 0.00066 | 0.00495 |
| 2.981 | $9.57 * 10^2$ | 0.00238 | 0.00011 | 0.00466 |
| 3.162 | $1.45 * 10^3$ | 0.00167 | 0.00000 | 0.00417 |
| 3.371 | $2.35 * 10^3$ | 0.00064 | 0.00000 | 0.00250 |
| 4.187 | $1.54 * 10^4$ | 0.00000 | 0.00000 | NA |

6.6 Plots and Tables with estimates and simultaneous confidence bands for Day 29

MOCK

6.6.1 Day 29 Spike protein antibody




Figure 6.21: Adjusted threshold-response function for a range of thresholds of the Day 29 Spike protein antibody levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed.

Table 6.21: Table of risk estimates for a range of thresholds of Day 29 Spike protein antibody levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 0.613 | $4.10 * 10^0$ | 0.00538 | 0.00327 | 0.00749 |
| 1.805 | $6.38 * 10^1$ | 0.00444 | 0.00246 | 0.00642 |
| 2.081 | $1.21 * 10^2$ | 0.00445 | 0.00233 | 0.00656 |
| 2.351 | $2.24 * 10^2$ | 0.00331 | 0.00144 | 0.00517 |
| 2.522 | $3.33 * 10^2$ | 0.00303 | 0.00105 | 0.00502 |
| 2.677 | $4.75 * 10^2$ | 0.00347 | 0.00096 | 0.00599 |
| 2.841 | $6.93 * 10^2$ | 0.00375 | 0.00079 | 0.00670 |
| 3.112 | $1.29 * 10^3$ | 0.00179 | 0.00000 | 0.00403 |
| 3.348 | $2.23 * 10^3$ | 0.00030 | 0.00000 | 0.00122 |
| 4.007 | $1.02 * 10^4$ | 0.00000 | 0.00000 | NA |

6.6.2 Day 29 RBD binding antibody




Figure 6.22: Adjusted threshold-response function for a range of thresholds of the Day 29 RBD binding antibody levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed.

Table 6.22: Table of risk estimates for a range of thresholds of Day 29 RBD binding antibody levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 0.834 | $6.82 * 10^0$ | 0.00538 | 0.00331 | 0.00744 |
| 1.892 | $7.80 * 10^1$ | 0.00493 | 0.00286 | 0.00699 |
| 2.273 | $1.87 * 10^2$ | 0.00434 | 0.00228 | 0.00640 |
| 2.575 | $3.76 * 10^2$ | 0.00379 | 0.00165 | 0.00594 |
| 2.780 | $6.03 * 10^2$ | 0.00401 | 0.00152 | 0.00649 |
| 2.960 | $9.12 * 10^2$ | 0.00454 | 0.00137 | 0.00771 |
| 3.144 | $1.39 * 10^3$ | 0.00454 | 0.00119 | 0.00789 |
| 3.461 | $2.89 * 10^3$ | 0.00405 | 0.00000 | 0.00826 |
| 3.736 | $5.45 * 10^3$ | 0.00917 | 0.00000 | 0.01956 |
| 4.211 | $1.63 * 10^4$ | 0.00434 | 0.00000 | 0.01880 |

6.6.3 Day 29 Pseudo virus-neutralizing antibody (50% titer)




Figure 6.23: Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed.

Table 6.23: Table of risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 0.083 | $1.21 * 10^0$ | 0.00538 | 0.00331 | 0.00744 |
| 0.779 | $6.01 * 10^0$ | 0.00487 | 0.00281 | 0.00692 |
| 0.988 | $9.73 * 10^0$ | 0.00458 | 0.00244 | 0.00671 |
| 1.147 | $1.40 * 10^1$ | 0.00470 | 0.00225 | 0.00716 |
| 1.271 | $1.87 * 10^1$ | 0.00411 | 0.00168 | 0.00654 |
| 1.382 | $2.41 * 10^1$ | 0.00327 | 0.00087 | 0.00567 |
| 1.481 | $3.03 * 10^1$ | 0.00294 | 0.00048 | 0.00540 |
| 1.656 | $4.53 * 10^1$ | 0.00357 | 0.00000 | 0.00717 |
| 1.852 | $7.11 * 10^1$ | 0.00600 | 0.00000 | 0.01356 |
| 2.879 | $7.57 * 10^2$ | 0.00000 | 0.00000 | NA |

6.6.4 Day 29 Pseudo virus-neutralizing antibody (80% titer)




Figure 6.24: Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed.

Table 6.24: Table of risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 0.876 | $7.52 * 10^0$ | 0.00538 | 0.00330 | 0.00745 |
| 1.260 | $1.82 * 10^1$ | 0.00494 | 0.00257 | 0.00730 |
| 1.339 | $2.18 * 10^1$ | 0.00474 | 0.00229 | 0.00719 |
| 1.440 | $2.75 * 10^1$ | 0.00381 | 0.00141 | 0.00620 |
| 1.541 | $3.48 * 10^1$ | 0.00267 | 0.00053 | 0.00481 |
| 1.610 | $4.07 * 10^1$ | 0.00293 | 0.00051 | 0.00535 |
| 1.707 | $5.09 * 10^1$ | 0.00246 | 0.00000 | 0.00511 |
| 1.839 | $6.90 * 10^1$ | 0.00205 | 0.00000 | 0.00527 |
| 1.956 | $9.04 * 10^1$ | 0.00049 | 0.00000 | 0.00197 |
| 2.719 | $5.24 * 10^2$ | 0.00000 | 0.00000 | NA |

6.7 Plots and Tables with estimates and pointwise confidence interval for Day 57 (monotone-corrected)

MOCK

6.7.1 Day 57 Spike protein binding antibody




Figure 6.25: Adjusted threshold-response function for a range of thresholds of the Day 57 Spike protein binding antibody levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 6.25: Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Spike protein binding antibody levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.316 | $2.07 * 10^1$ | 0.00468 | 0.00288 | 0.00648 |
| 2.657 | $4.54 * 10^2$ | 0.00420 | 0.00247 | 0.00593 |
| 2.951 | $8.93 * 10^2$ | 0.00344 | 0.00182 | 0.00505 |
| 3.221 | $1.66 * 10^3$ | 0.00270 | 0.00127 | 0.00412 |
| 3.394 | $2.48 * 10^3$ | 0.00256 | 0.00114 | 0.00397 |
| 3.544 | $3.50 * 10^3$ | 0.00201 | 0.00068 | 0.00333 |
| 3.658 | $4.55 * 10^3$ | 0.00162 | 0.00042 | 0.00283 |
| 3.841 | $6.93 * 10^3$ | 0.00131 | 0.00018 | 0.00244 |
| 3.973 | $9.40 * 10^3$ | 0.00115 | 0.00008 | 0.00222 |
| 4.007 | $1.02 * 10^4$ | 0.00115 | 0.00000 | 0.00241 |

6.7.2 Day 57 RBD binding antibody




Figure 6.26: Adjusted threshold-response function for a range of thresholds of the Day 57 RBD binding antibody levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 6.26: Table of monotone-corrected risk estimates for a range of thresholds of Day 57 RBD binding antibody levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|--------------------|---------------|---------|----------|
| 1.073 | 1.18×10^1 | 0.00468 | 0.00293 | 0.00643 |
| 2.715 | 5.19×10^2 | 0.00440 | 0.00266 | 0.00614 |
| 3.022 | 1.05×10^3 | 0.00406 | 0.00233 | 0.00578 |
| 3.338 | 2.18×10^3 | 0.00338 | 0.00170 | 0.00506 |
| 3.514 | 3.27×10^3 | 0.00338 | 0.00174 | 0.00502 |
| 3.657 | 4.54×10^3 | 0.00338 | 0.00153 | 0.00523 |
| 3.797 | 6.27×10^3 | 0.00338 | 0.00145 | 0.00531 |
| 3.986 | 9.68×10^3 | 0.00338 | 0.00101 | 0.00575 |
| 4.125 | 1.33×10^4 | 0.00338 | 0.00079 | 0.00597 |
| 4.211 | 1.63×10^4 | 0.00309 | 0.00076 | 0.00543 |

6.7.3 Day 57 Pseudo virus-neutralizing antibody (50% titer)




Figure 6.27: Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 6.27: Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.135 | $1.36 * 10^1$ | 0.00468 | 0.00274 | 0.00662 |
| 2.055 | $1.14 * 10^2$ | 0.00412 | 0.00222 | 0.00601 |
| 2.281 | $1.91 * 10^2$ | 0.00412 | 0.00205 | 0.00618 |
| 2.519 | $3.30 * 10^2$ | 0.00349 | 0.00144 | 0.00554 |
| 2.657 | $4.54 * 10^2$ | 0.00267 | 0.00085 | 0.00448 |
| 2.828 | $6.73 * 10^2$ | 0.00267 | 0.00038 | 0.00495 |
| 2.959 | $9.10 * 10^2$ | 0.00267 | 0.00000 | 0.00546 |
| 3.174 | $1.49 * 10^3$ | 0.00217 | 0.00000 | 0.00490 |
| 3.387 | $2.44 * 10^3$ | 0.00125 | 0.00000 | 0.00420 |
| 4.038 | $1.09 * 10^4$ | 0.00000 | 0.00000 | NA |

6.7.4 Day 57 Pseudo virus-neutralizing antibody (80% titer)




Figure 6.28: Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 6.28: Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|--------------------|---------------|---------|----------|
| 1.403 | 2.53×10^1 | 0.00469 | 0.00278 | 0.00660 |
| 2.220 | 1.66×10^2 | 0.00420 | 0.00230 | 0.00610 |
| 2.455 | 2.85×10^2 | 0.00367 | 0.00183 | 0.00552 |
| 2.644 | 4.41×10^2 | 0.00367 | 0.00156 | 0.00578 |
| 2.764 | 5.81×10^2 | 0.00300 | 0.00106 | 0.00495 |
| 2.874 | 7.48×10^2 | 0.00280 | 0.00066 | 0.00495 |
| 2.981 | 9.57×10^2 | 0.00238 | 0.00011 | 0.00466 |
| 3.162 | 1.45×10^3 | 0.00190 | 0.00000 | 0.00439 |
| 3.371 | 2.35×10^3 | 0.00085 | 0.00000 | 0.00271 |
| 4.187 | 1.54×10^4 | 0.00000 | 0.00000 | NA |

6.8 Plots and Tables with estimates and pointwise confidence intervals for Day 29 (monotone-corrected)

MOCK

6.8.1 Day 29 Spike protein antibody




Figure 6.29: Adjusted threshold-response function for a range of thresholds of the Day 29 Spike protein antibody levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 6.29: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Spike protein antibody levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 0.613 | $4.10 * 10^0$ | 0.00538 | 0.00327 | 0.00749 |
| 1.805 | $6.38 * 10^1$ | 0.00450 | 0.00253 | 0.00648 |
| 2.081 | $1.21 * 10^2$ | 0.00445 | 0.00233 | 0.00656 |
| 2.351 | $2.24 * 10^2$ | 0.00343 | 0.00157 | 0.00529 |
| 2.522 | $3.33 * 10^2$ | 0.00343 | 0.00145 | 0.00541 |
| 2.677 | $4.75 * 10^2$ | 0.00343 | 0.00091 | 0.00595 |
| 2.841 | $6.93 * 10^2$ | 0.00343 | 0.00048 | 0.00638 |
| 3.112 | $1.29 * 10^3$ | 0.00179 | 0.00000 | 0.00403 |
| 3.348 | $2.23 * 10^3$ | 0.00035 | 0.00000 | 0.00127 |
| 4.007 | $1.02 * 10^4$ | 0.00000 | 0.00000 | NA |

6.8.2 Day 29 RBD binding antibody




Figure 6.30: Adjusted threshold-response function for a range of thresholds of the Day 29 RBD binding antibody levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 6.30: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 RBD binding antibody levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 0.834 | $6.82 * 10^0$ | 0.00538 | 0.00331 | 0.00744 |
| 1.892 | $7.80 * 10^1$ | 0.00493 | 0.00286 | 0.00699 |
| 2.273 | $1.87 * 10^2$ | 0.00458 | 0.00252 | 0.00663 |
| 2.575 | $3.76 * 10^2$ | 0.00458 | 0.00243 | 0.00672 |
| 2.780 | $6.03 * 10^2$ | 0.00458 | 0.00209 | 0.00706 |
| 2.960 | $9.12 * 10^2$ | 0.00458 | 0.00141 | 0.00775 |
| 3.144 | $1.39 * 10^3$ | 0.00458 | 0.00122 | 0.00793 |
| 3.461 | $2.89 * 10^3$ | 0.00458 | 0.00037 | 0.00879 |
| 3.736 | $5.45 * 10^3$ | 0.00458 | 0.00000 | 0.01497 |
| 4.211 | $1.63 * 10^4$ | 0.00429 | 0.00000 | 0.01875 |

6.8.3 Day 29 Pseudo virus-neutralizing antibody (50% titer)




Figure 6.31: Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 6.31: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 0.083 | $1.21 * 10^0$ | 0.00538 | 0.00331 | 0.00744 |
| 0.779 | $6.01 * 10^0$ | 0.00487 | 0.00281 | 0.00692 |
| 0.988 | $9.73 * 10^0$ | 0.00478 | 0.00264 | 0.00691 |
| 1.147 | $1.40 * 10^1$ | 0.00474 | 0.00229 | 0.00720 |
| 1.271 | $1.87 * 10^1$ | 0.00418 | 0.00175 | 0.00661 |
| 1.382 | $2.41 * 10^1$ | 0.00418 | 0.00178 | 0.00658 |
| 1.481 | $3.03 * 10^1$ | 0.00418 | 0.00172 | 0.00664 |
| 1.656 | $4.53 * 10^1$ | 0.00418 | 0.00058 | 0.00778 |
| 1.852 | $7.11 * 10^1$ | 0.00418 | 0.00000 | 0.01174 |
| 2.879 | $7.57 * 10^2$ | 0.00000 | 0.00000 | NA |

6.8.4 Day 29 Pseudo virus-neutralizing antibody (80% titer)




Figure 6.32: Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals. The dashed red line marks the threshold after which no more COVID events are observed. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 6.32: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 0.876 | $7.52 * 10^0$ | 0.00538 | 0.00330 | 0.00745 |
| 1.260 | $1.82 * 10^1$ | 0.00489 | 0.00252 | 0.00725 |
| 1.339 | $2.18 * 10^1$ | 0.00474 | 0.00229 | 0.00719 |
| 1.440 | $2.75 * 10^1$ | 0.00389 | 0.00150 | 0.00629 |
| 1.541 | $3.48 * 10^1$ | 0.00276 | 0.00062 | 0.00490 |
| 1.610 | $4.07 * 10^1$ | 0.00276 | 0.00034 | 0.00519 |
| 1.707 | $5.09 * 10^1$ | 0.00246 | 0.00000 | 0.00511 |
| 1.839 | $6.90 * 10^1$ | 0.00205 | 0.00000 | 0.00527 |
| 1.956 | $9.04 * 10^1$ | 0.00047 | 0.00000 | 0.00195 |
| 2.719 | $5.24 * 10^2$ | 0.00000 | 0.00000 | NA |

MOCK

Chapter 7

Univariate CoR: Nonparametric Threshold Modeling ($\leq s$)

The same methodology as the previous section is apply to estimate the “below” threshold-response function $E_{W|A=1}[Y = 1 | A = 1, X, S \leq s]$.

7.1 Plots and Tables with estimates and pointwise confidence interval for Day 57

7.1.1 Day 57 Spike protein binding antibody




Figure 7.1: Adjusted threshold-response function for a range of thresholds of the Day 57 Spike protein binding antibody levels with pointwise 95% confidence intervals.

Table 7.1: Table of risk estimates for a range of thresholds of Day 57 Spike protein binding antibody levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 2.450 | $2.82 * 10^2$ | 0.00610 | 0.00000 | 0.01713 |
| 2.815 | $6.53 * 10^2$ | 0.01621 | 0.00241 | 0.03000 |
| 3.033 | $1.08 * 10^3$ | 0.01570 | 0.00791 | 0.02348 |
| 3.221 | $1.66 * 10^3$ | 0.01386 | 0.00693 | 0.02080 |
| 3.394 | $2.48 * 10^3$ | 0.01106 | 0.00512 | 0.01699 |
| 3.603 | $4.01 * 10^3$ | 0.01097 | 0.00591 | 0.01604 |
| 3.716 | $5.20 * 10^3$ | 0.00948 | 0.00566 | 0.01330 |
| 3.841 | $6.93 * 10^3$ | 0.00854 | 0.00538 | 0.01170 |
| 3.973 | $9.40 * 10^3$ | 0.00774 | 0.00506 | 0.01041 |
| 4.007 | $1.02 * 10^4$ | 0.00468 | 0.00334 | 0.00602 |

7.1.2 Day 57 RBD binding antibody




Figure 7.2: Adjusted threshold-response function for a range of thresholds of the Day 57 RBD binding antibody levels with pointwise 95% confidence intervals.

Table 7.2: Table of risk estimates for a range of thresholds of Day 57 RBD binding antibody levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 2.478 | $3.01 * 10^2$ | 0.00835 | 0.00000 | 0.01712 |
| 2.882 | $7.62 * 10^2$ | 0.01506 | 0.00670 | 0.02341 |
| 3.132 | $1.36 * 10^3$ | 0.01167 | 0.00567 | 0.01767 |
| 3.338 | $2.18 * 10^3$ | 0.01174 | 0.00637 | 0.01712 |
| 3.514 | $3.27 * 10^3$ | 0.00996 | 0.00560 | 0.01432 |
| 3.722 | $5.27 * 10^3$ | 0.00776 | 0.00460 | 0.01092 |
| 3.866 | $7.35 * 10^3$ | 0.00622 | 0.00373 | 0.00871 |
| 3.986 | $9.68 * 10^3$ | 0.00569 | 0.00356 | 0.00782 |
| 4.125 | $1.33 * 10^4$ | 0.00548 | 0.00360 | 0.00737 |
| 4.211 | $1.63 * 10^4$ | 0.00468 | 0.00334 | 0.00602 |

7.1.3 Day 57 Pseudo virus-neutralizing antibody (50% titer)




Figure 7.3: Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals.

Table 7.3: Table of risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.765 | $5.82 * 10^1$ | 0.00948 | 0.00000 | 0.02037 |
| 2.143 | $1.39 * 10^2$ | 0.01259 | 0.00450 | 0.02068 |
| 2.345 | $2.21 * 10^2$ | 0.00760 | 0.00365 | 0.01155 |
| 2.519 | $3.30 * 10^2$ | 0.00689 | 0.00404 | 0.00973 |
| 2.657 | $4.54 * 10^2$ | 0.00882 | 0.00569 | 0.01195 |
| 2.867 | $7.36 * 10^2$ | 0.00656 | 0.00434 | 0.00877 |
| 3.005 | $1.01 * 10^3$ | 0.00613 | 0.00418 | 0.00808 |
| 3.174 | $1.49 * 10^3$ | 0.00552 | 0.00385 | 0.00719 |
| 3.387 | $2.44 * 10^3$ | 0.00525 | 0.00375 | 0.00675 |
| 4.038 | $1.09 * 10^4$ | 0.00468 | 0.00334 | 0.00602 |

7.1.4 Day 57 Pseudo virus-neutralizing antibody (80% titer)




Figure 7.4: Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals.

Table 7.4: Table of risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.954 | $8.99 * 10^1$ | 0.00451 | 0.00000 | 0.01036 |
| 2.309 | $2.04 * 10^2$ | 0.00912 | 0.00350 | 0.01474 |
| 2.516 | $3.28 * 10^2$ | 0.00851 | 0.00466 | 0.01237 |
| 2.644 | $4.41 * 10^2$ | 0.00645 | 0.00389 | 0.00901 |
| 2.764 | $5.81 * 10^2$ | 0.00691 | 0.00429 | 0.00953 |
| 2.909 | $8.11 * 10^2$ | 0.00635 | 0.00429 | 0.00840 |
| 3.031 | $1.07 * 10^3$ | 0.00599 | 0.00415 | 0.00784 |
| 3.162 | $1.45 * 10^3$ | 0.00562 | 0.00395 | 0.00729 |
| 3.371 | $2.35 * 10^3$ | 0.00521 | 0.00371 | 0.00671 |
| 4.187 | $1.54 * 10^4$ | 0.00468 | 0.00334 | 0.00602 |

7.2 Plots and Tables with estimates and pointwise confidence intervals for Day 29

MOCK

7.2.1 Day 29 Spike protein antibody




Figure 7.5: Adjusted threshold-response function for a range of thresholds of the Day 29 Spike protein antibody levels with pointwise 95% confidence intervals.

Table 7.5: Table of risk estimates for a range of thresholds of Day 29 Spike protein antibody levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.532 | $3.40 * 10^1$ | 0.01324 | 0.00000 | 0.03712 |
| 1.886 | $7.69 * 10^1$ | 0.02528 | 0.00999 | 0.04058 |
| 2.138 | $1.37 * 10^2$ | 0.01132 | 0.00453 | 0.01811 |
| 2.351 | $2.24 * 10^2$ | 0.01002 | 0.00498 | 0.01506 |
| 2.522 | $3.33 * 10^2$ | 0.00899 | 0.00562 | 0.01235 |
| 2.733 | $5.41 * 10^2$ | 0.00682 | 0.00442 | 0.00922 |
| 2.903 | $8.00 * 10^2$ | 0.00646 | 0.00442 | 0.00850 |
| 3.112 | $1.29 * 10^3$ | 0.00638 | 0.00446 | 0.00829 |
| 3.348 | $2.23 * 10^3$ | 0.00609 | 0.00443 | 0.00775 |
| 4.007 | $1.02 * 10^4$ | 0.00538 | 0.00392 | 0.00683 |

7.2.2 Day 29 RBD binding antibody




Figure 7.6: Adjusted threshold-response function for a range of thresholds of the Day 29 RBD binding antibody levels with pointwise 95% confidence intervals.

Table 7.6: Table of risk estimates for a range of thresholds of Day 29 RBD binding antibody levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.620 | $4.17 * 10^1$ | 0.01845 | 0.00000 | 0.04875 |
| 2.052 | $1.13 * 10^2$ | 0.01775 | 0.00537 | 0.03012 |
| 2.345 | $2.21 * 10^2$ | 0.01112 | 0.00554 | 0.01670 |
| 2.575 | $3.76 * 10^2$ | 0.01000 | 0.00540 | 0.01459 |
| 2.780 | $6.03 * 10^2$ | 0.00851 | 0.00520 | 0.01182 |
| 3.010 | $1.02 * 10^3$ | 0.00693 | 0.00460 | 0.00927 |
| 3.217 | $1.65 * 10^3$ | 0.00603 | 0.00414 | 0.00792 |
| 3.461 | $2.89 * 10^3$ | 0.00617 | 0.00438 | 0.00795 |
| 3.736 | $5.45 * 10^3$ | 0.00540 | 0.00386 | 0.00693 |
| 4.211 | $1.63 * 10^4$ | 0.00538 | 0.00392 | 0.00683 |

7.2.3 Day 29 Pseudo virus-neutralizing antibody (50% titer)




Figure 7.7: Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals.

Table 7.7: Table of risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals.

| log ₁₀ -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------------|---------------|---------------|---------|----------|
| 0.548 | $3.53 * 10^0$ | 0.05182 | 0.03313 | 0.07050 |
| 0.873 | $7.46 * 10^0$ | 0.01181 | 0.00408 | 0.01953 |
| 1.032 | $1.08 * 10^1$ | 0.00819 | 0.00441 | 0.01196 |
| 1.147 | $1.40 * 10^1$ | 0.00702 | 0.00408 | 0.00996 |
| 1.271 | $1.87 * 10^1$ | 0.00713 | 0.00459 | 0.00967 |
| 1.427 | $2.67 * 10^1$ | 0.00747 | 0.00502 | 0.00991 |
| 1.526 | $3.36 * 10^1$ | 0.00653 | 0.00447 | 0.00860 |
| 1.656 | $4.53 * 10^1$ | 0.00594 | 0.00419 | 0.00768 |
| 1.852 | $7.11 * 10^1$ | 0.00543 | 0.00389 | 0.00696 |
| 2.879 | $7.57 * 10^2$ | 0.00538 | 0.00392 | 0.00683 |

7.2.4 Day 29 Pseudo virus-neutralizing antibody (80% titer)




Figure 7.8: Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals.

Table 7.8: Table of risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.183 | $1.52 * 10^1$ | 0.00750 | 0.00387 | 0.01113 |
| 1.300 | $2.00 * 10^1$ | 0.00567 | 0.00313 | 0.00821 |
| 1.385 | $2.43 * 10^1$ | 0.00669 | 0.00413 | 0.00925 |
| 1.477 | $3.00 * 10^1$ | 0.00728 | 0.00481 | 0.00976 |
| 1.541 | $3.48 * 10^1$ | 0.00783 | 0.00541 | 0.01025 |
| 1.632 | $4.29 * 10^1$ | 0.00694 | 0.00493 | 0.00895 |
| 1.707 | $5.09 * 10^1$ | 0.00659 | 0.00470 | 0.00848 |
| 1.839 | $6.90 * 10^1$ | 0.00632 | 0.00459 | 0.00805 |
| 1.956 | $9.04 * 10^1$ | 0.00605 | 0.00441 | 0.00769 |
| 2.719 | $5.24 * 10^2$ | 0.00538 | 0.00392 | 0.00683 |

7.3 Plots and Tables with estimates and pointwise confidence interval for Day 57 (monotone-corrected)

MOCK

7.3.1 Day 57 Spike protein binding antibody




Figure 7.9: Adjusted threshold-response function for a range of thresholds of the Day 57 Spike protein binding antibody levels with pointwise 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.9: Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Spike protein binding antibody levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 2.450 | $2.82 * 10^2$ | 0.01511 | 0.00408 | 0.02614 |
| 2.815 | $6.53 * 10^2$ | 0.01511 | 0.00132 | 0.02890 |
| 3.033 | $1.08 * 10^3$ | 0.01511 | 0.00732 | 0.02289 |
| 3.221 | $1.66 * 10^3$ | 0.01386 | 0.00693 | 0.02080 |
| 3.394 | $2.48 * 10^3$ | 0.01158 | 0.00564 | 0.01751 |
| 3.603 | $4.01 * 10^3$ | 0.01097 | 0.00591 | 0.01604 |
| 3.716 | $5.20 * 10^3$ | 0.00948 | 0.00566 | 0.01330 |
| 3.841 | $6.93 * 10^3$ | 0.00854 | 0.00538 | 0.01170 |
| 3.973 | $9.40 * 10^3$ | 0.00774 | 0.00506 | 0.01041 |
| 4.007 | $1.02 * 10^4$ | 0.00468 | 0.00334 | 0.00602 |

7.3.2 Day 57 RBD binding antibody




Figure 7.10: Adjusted threshold-response function for a range of thresholds of the Day 57 RBD binding antibody levels with pointwise 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.10: Table of monotone-corrected risk estimates for a range of thresholds of Day 57 RBD binding antibody levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 2.478 | $3.01 * 10^2$ | 0.01500 | 0.00624 | 0.02377 |
| 2.882 | $7.62 * 10^2$ | 0.01500 | 0.00665 | 0.02336 |
| 3.132 | $1.36 * 10^3$ | 0.01221 | 0.00621 | 0.01821 |
| 3.338 | $2.18 * 10^3$ | 0.01174 | 0.00637 | 0.01712 |
| 3.514 | $3.27 * 10^3$ | 0.00996 | 0.00560 | 0.01432 |
| 3.722 | $5.27 * 10^3$ | 0.00776 | 0.00460 | 0.01092 |
| 3.866 | $7.35 * 10^3$ | 0.00622 | 0.00373 | 0.00871 |
| 3.986 | $9.68 * 10^3$ | 0.00569 | 0.00356 | 0.00782 |
| 4.125 | $1.33 * 10^4$ | 0.00546 | 0.00358 | 0.00735 |
| 4.211 | $1.63 * 10^4$ | 0.00468 | 0.00334 | 0.00602 |

7.3.3 Day 57 Pseudo virus-neutralizing antibody (50% titer)




Figure 7.11: Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.11: Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.765 | $5.82 * 10^1$ | 0.01328 | 0.00238 | 0.02418 |
| 2.143 | $1.39 * 10^2$ | 0.01259 | 0.00450 | 0.02068 |
| 2.345 | $2.21 * 10^2$ | 0.00760 | 0.00365 | 0.01155 |
| 2.519 | $3.30 * 10^2$ | 0.00730 | 0.00446 | 0.01015 |
| 2.657 | $4.54 * 10^2$ | 0.00730 | 0.00417 | 0.01043 |
| 2.867 | $7.36 * 10^2$ | 0.00656 | 0.00434 | 0.00877 |
| 3.005 | $1.01 * 10^3$ | 0.00611 | 0.00416 | 0.00806 |
| 3.174 | $1.49 * 10^3$ | 0.00552 | 0.00385 | 0.00719 |
| 3.387 | $2.44 * 10^3$ | 0.00525 | 0.00375 | 0.00675 |
| 4.038 | $1.09 * 10^4$ | 0.00468 | 0.00334 | 0.00602 |

7.3.4 Day 57 Pseudo virus-neutralizing antibody (80% titer)




Figure 7.12: Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.12: Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.954 | $8.99 * 10^1$ | 0.00807 | 0.00223 | 0.01392 |
| 2.309 | $2.04 * 10^2$ | 0.00807 | 0.00245 | 0.01369 |
| 2.516 | $3.28 * 10^2$ | 0.00807 | 0.00422 | 0.01193 |
| 2.644 | $4.41 * 10^2$ | 0.00685 | 0.00429 | 0.00941 |
| 2.764 | $5.81 * 10^2$ | 0.00673 | 0.00411 | 0.00935 |
| 2.909 | $8.11 * 10^2$ | 0.00635 | 0.00429 | 0.00840 |
| 3.031 | $1.07 * 10^3$ | 0.00599 | 0.00415 | 0.00784 |
| 3.162 | $1.45 * 10^3$ | 0.00562 | 0.00395 | 0.00729 |
| 3.371 | $2.35 * 10^3$ | 0.00519 | 0.00369 | 0.00669 |
| 4.187 | $1.54 * 10^4$ | 0.00468 | 0.00334 | 0.00602 |

7.4 Plots and Tables with estimates and pointwise confidence intervals for Day 29 (monotone-corrected)

MOCK

7.4.1 Day 29 Spike protein antibody




Figure 7.13: Adjusted threshold-response function for a range of thresholds of the Day 29 Spike protein antibody levels with pointwise 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.13: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Spike protein antibody levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.532 | $3.40 * 10^1$ | 0.02025 | 0.00000 | 0.04412 |
| 1.886 | $7.69 * 10^1$ | 0.02025 | 0.00496 | 0.03554 |
| 2.138 | $1.37 * 10^2$ | 0.01159 | 0.00480 | 0.01838 |
| 2.351 | $2.24 * 10^2$ | 0.01002 | 0.00498 | 0.01506 |
| 2.522 | $3.33 * 10^2$ | 0.00899 | 0.00562 | 0.01235 |
| 2.733 | $5.41 * 10^2$ | 0.00684 | 0.00444 | 0.00924 |
| 2.903 | $8.00 * 10^2$ | 0.00656 | 0.00452 | 0.00860 |
| 3.112 | $1.29 * 10^3$ | 0.00638 | 0.00446 | 0.00829 |
| 3.348 | $2.23 * 10^3$ | 0.00609 | 0.00443 | 0.00775 |
| 4.007 | $1.02 * 10^4$ | 0.00538 | 0.00392 | 0.00683 |

7.4.2 Day 29 RBD binding antibody




Figure 7.14: Adjusted threshold-response function for a range of thresholds of the Day 29 RBD binding antibody levels with pointwise 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.14: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 RBD binding antibody levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.620 | $4.17 * 10^1$ | 0.02409 | 0.00000 | 0.05439 |
| 2.052 | $1.13 * 10^2$ | 0.01767 | 0.00529 | 0.03004 |
| 2.345 | $2.21 * 10^2$ | 0.01117 | 0.00559 | 0.01675 |
| 2.575 | $3.76 * 10^2$ | 0.01000 | 0.00540 | 0.01459 |
| 2.780 | $6.03 * 10^2$ | 0.00851 | 0.00520 | 0.01182 |
| 3.010 | $1.02 * 10^3$ | 0.00693 | 0.00460 | 0.00927 |
| 3.217 | $1.65 * 10^3$ | 0.00609 | 0.00420 | 0.00798 |
| 3.461 | $2.89 * 10^3$ | 0.00609 | 0.00431 | 0.00788 |
| 3.736 | $5.45 * 10^3$ | 0.00544 | 0.00391 | 0.00698 |
| 4.211 | $1.63 * 10^4$ | 0.00538 | 0.00392 | 0.00683 |

7.4.3 Day 29 Pseudo virus-neutralizing antibody (50% titer)




Figure 7.15: Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.15: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 0.548 | $3.53 * 10^0$ | 0.05182 | 0.03313 | 0.07050 |
| 0.873 | $7.46 * 10^0$ | 0.01181 | 0.00408 | 0.01953 |
| 1.032 | $1.08 * 10^1$ | 0.00819 | 0.00441 | 0.01196 |
| 1.147 | $1.40 * 10^1$ | 0.00721 | 0.00427 | 0.01015 |
| 1.271 | $1.87 * 10^1$ | 0.00721 | 0.00467 | 0.00975 |
| 1.427 | $2.67 * 10^1$ | 0.00721 | 0.00477 | 0.00965 |
| 1.526 | $3.36 * 10^1$ | 0.00653 | 0.00447 | 0.00860 |
| 1.656 | $4.53 * 10^1$ | 0.00594 | 0.00419 | 0.00768 |
| 1.852 | $7.11 * 10^1$ | 0.00550 | 0.00396 | 0.00704 |
| 2.879 | $7.57 * 10^2$ | 0.00538 | 0.00392 | 0.00683 |

7.4.4 Day 29 Pseudo virus-neutralizing antibody (80% titer)




Figure 7.16: Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.16: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with pointwise 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.183 | $1.52 * 10^1$ | 0.00750 | 0.00387 | 0.01113 |
| 1.300 | $2.00 * 10^1$ | 0.00699 | 0.00445 | 0.00953 |
| 1.385 | $2.43 * 10^1$ | 0.00699 | 0.00443 | 0.00955 |
| 1.477 | $3.00 * 10^1$ | 0.00699 | 0.00451 | 0.00946 |
| 1.541 | $3.48 * 10^1$ | 0.00699 | 0.00457 | 0.00941 |
| 1.632 | $4.29 * 10^1$ | 0.00694 | 0.00493 | 0.00895 |
| 1.707 | $5.09 * 10^1$ | 0.00659 | 0.00470 | 0.00848 |
| 1.839 | $6.90 * 10^1$ | 0.00632 | 0.00459 | 0.00805 |
| 1.956 | $9.04 * 10^1$ | 0.00605 | 0.00441 | 0.00769 |
| 2.719 | $5.24 * 10^2$ | 0.00538 | 0.00392 | 0.00683 |

7.5 Plots and Tables with estimates and simultaneous confidence bands for Day 57

MOCK

7.5.1 Day 57 Spike protein binding antibody




Figure 7.17: Adjusted threshold-response function for a range of thresholds of the Day 57 Spike protein binding antibody levels with simultaneous 95% confidence intervals.

Table 7.17: Table of risk estimates for a range of thresholds of Day 57 Spike protein binding antibody levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 2.450 | $2.82 * 10^2$ | 0.00610 | 0.00000 | 0.02142 |
| 2.815 | $6.53 * 10^2$ | 0.01621 | 0.00000 | 0.03537 |
| 3.033 | $1.08 * 10^3$ | 0.01570 | 0.00488 | 0.02651 |
| 3.221 | $1.66 * 10^3$ | 0.01386 | 0.00423 | 0.02350 |
| 3.394 | $2.48 * 10^3$ | 0.01106 | 0.00281 | 0.01930 |
| 3.603 | $4.01 * 10^3$ | 0.01097 | 0.00394 | 0.01801 |
| 3.716 | $5.20 * 10^3$ | 0.00948 | 0.00417 | 0.01479 |
| 3.841 | $6.93 * 10^3$ | 0.00854 | 0.00416 | 0.01293 |
| 3.973 | $9.40 * 10^3$ | 0.00774 | 0.00402 | 0.01146 |
| 4.007 | $1.02 * 10^4$ | 0.00468 | 0.00281 | 0.00654 |

7.5.2 Day 57 RBD binding antibody




Figure 7.18: Adjusted threshold-response function for a range of thresholds of the Day 57 RBD binding antibody levels with simultaneous 95% confidence intervals.

Table 7.18: Table of risk estimates for a range of thresholds of Day 57 RBD binding antibody levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 2.478 | $3.01 * 10^2$ | 0.00835 | 0.00000 | 0.02039 |
| 2.882 | $7.62 * 10^2$ | 0.01506 | 0.00359 | 0.02653 |
| 3.132 | $1.36 * 10^3$ | 0.01167 | 0.00343 | 0.01991 |
| 3.338 | $2.18 * 10^3$ | 0.01174 | 0.00436 | 0.01913 |
| 3.514 | $3.27 * 10^3$ | 0.00996 | 0.00397 | 0.01595 |
| 3.722 | $5.27 * 10^3$ | 0.00776 | 0.00342 | 0.01210 |
| 3.866 | $7.35 * 10^3$ | 0.00622 | 0.00280 | 0.00964 |
| 3.986 | $9.68 * 10^3$ | 0.00569 | 0.00276 | 0.00862 |
| 4.125 | $1.33 * 10^4$ | 0.00548 | 0.00290 | 0.00807 |
| 4.211 | $1.63 * 10^4$ | 0.00468 | 0.00284 | 0.00652 |

7.5.3 Day 57 Pseudo virus-neutralizing antibody (50% titer)




Figure 7.19: Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals.

Table 7.19: Table of risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.765 | $5.82 * 10^1$ | 0.00948 | 0.00000 | 0.02441 |
| 2.143 | $1.39 * 10^2$ | 0.01259 | 0.00151 | 0.02368 |
| 2.345 | $2.21 * 10^2$ | 0.00760 | 0.00219 | 0.01301 |
| 2.519 | $3.30 * 10^2$ | 0.00689 | 0.00299 | 0.01079 |
| 2.657 | $4.54 * 10^2$ | 0.00882 | 0.00453 | 0.01311 |
| 2.867 | $7.36 * 10^2$ | 0.00656 | 0.00353 | 0.00959 |
| 3.005 | $1.01 * 10^3$ | 0.00613 | 0.00346 | 0.00880 |
| 3.174 | $1.49 * 10^3$ | 0.00552 | 0.00323 | 0.00781 |
| 3.387 | $2.44 * 10^3$ | 0.00525 | 0.00320 | 0.00731 |
| 4.038 | $1.09 * 10^4$ | 0.00468 | 0.00284 | 0.00651 |

7.5.4 Day 57 Pseudo virus-neutralizing antibody (80% titer)




Figure 7.20: Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals.

Table 7.20: Table of risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.954 | $8.99 * 10^1$ | 0.00451 | 0.00000 | 0.01252 |
| 2.309 | $2.04 * 10^2$ | 0.00912 | 0.00142 | 0.01682 |
| 2.516 | $3.28 * 10^2$ | 0.00851 | 0.00323 | 0.01380 |
| 2.644 | $4.41 * 10^2$ | 0.00645 | 0.00295 | 0.00996 |
| 2.764 | $5.81 * 10^2$ | 0.00691 | 0.00332 | 0.01050 |
| 2.909 | $8.11 * 10^2$ | 0.00635 | 0.00353 | 0.00916 |
| 3.031 | $1.07 * 10^3$ | 0.00599 | 0.00347 | 0.00852 |
| 3.162 | $1.45 * 10^3$ | 0.00562 | 0.00333 | 0.00791 |
| 3.371 | $2.35 * 10^3$ | 0.00521 | 0.00316 | 0.00726 |
| 4.187 | $1.54 * 10^4$ | 0.00468 | 0.00284 | 0.00651 |

7.6 Plots and Tables with estimates and simultaneous confidence bands for Day 29

MOCK

7.6.1 Day 29 Spike protein antibody




Figure 7.21: Adjusted threshold-response function for a range of thresholds of the Day 29 Spike protein antibody levels with simultaneous 95% confidence intervals.

Table 7.21: Table of risk estimates for a range of thresholds of Day 29 Spike protein antibody levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.532 | $3.40 * 10^1$ | 0.01324 | 0.00000 | 0.04628 |
| 1.886 | $7.69 * 10^1$ | 0.02528 | 0.00412 | 0.04645 |
| 2.138 | $1.37 * 10^2$ | 0.01132 | 0.00192 | 0.02071 |
| 2.351 | $2.24 * 10^2$ | 0.01002 | 0.00304 | 0.01699 |
| 2.522 | $3.33 * 10^2$ | 0.00899 | 0.00433 | 0.01364 |
| 2.733 | $5.41 * 10^2$ | 0.00682 | 0.00350 | 0.01014 |
| 2.903 | $8.00 * 10^2$ | 0.00646 | 0.00364 | 0.00928 |
| 3.112 | $1.29 * 10^3$ | 0.00638 | 0.00373 | 0.00903 |
| 3.348 | $2.23 * 10^3$ | 0.00609 | 0.00379 | 0.00839 |
| 4.007 | $1.02 * 10^4$ | 0.00538 | 0.00336 | 0.00739 |

7.6.2 Day 29 RBD binding antibody




Figure 7.22: Adjusted threshold-response function for a range of thresholds of the Day 29 RBD binding antibody levels with simultaneous 95% confidence intervals.

Table 7.22: Table of risk estimates for a range of thresholds of Day 29 RBD binding antibody levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.620 | $4.17 * 10^1$ | 0.01845 | 0.00000 | 0.06045 |
| 2.052 | $1.13 * 10^2$ | 0.01775 | 0.00059 | 0.03491 |
| 2.345 | $2.21 * 10^2$ | 0.01112 | 0.00338 | 0.01885 |
| 2.575 | $3.76 * 10^2$ | 0.01000 | 0.00363 | 0.01636 |
| 2.780 | $6.03 * 10^2$ | 0.00851 | 0.00392 | 0.01310 |
| 3.010 | $1.02 * 10^3$ | 0.00693 | 0.00370 | 0.01017 |
| 3.217 | $1.65 * 10^3$ | 0.00603 | 0.00341 | 0.00865 |
| 3.461 | $2.89 * 10^3$ | 0.00617 | 0.00369 | 0.00864 |
| 3.736 | $5.45 * 10^3$ | 0.00540 | 0.00326 | 0.00753 |
| 4.211 | $1.63 * 10^4$ | 0.00538 | 0.00336 | 0.00740 |

7.6.3 Day 29 Pseudo virus-neutralizing antibody (50% titer)




Figure 7.23: Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals.

Table 7.23: Table of risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals.

| log ₁₀ -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------------|------------------------|---------------|---------|----------|
| 0.548 | 3.53 * 10 ⁰ | 0.05182 | 0.02597 | 0.07766 |
| 0.873 | 7.46 * 10 ⁰ | 0.01181 | 0.00112 | 0.02249 |
| 1.032 | 1.08 * 10 ¹ | 0.00819 | 0.00296 | 0.01341 |
| 1.147 | 1.40 * 10 ¹ | 0.00702 | 0.00295 | 0.01108 |
| 1.271 | 1.87 * 10 ¹ | 0.00713 | 0.00362 | 0.01064 |
| 1.427 | 2.67 * 10 ¹ | 0.00747 | 0.00409 | 0.01084 |
| 1.526 | 3.36 * 10 ¹ | 0.00653 | 0.00367 | 0.00939 |
| 1.656 | 4.53 * 10 ¹ | 0.00594 | 0.00353 | 0.00835 |
| 1.852 | 7.11 * 10 ¹ | 0.00543 | 0.00330 | 0.00755 |
| 2.879 | 7.57 * 10 ² | 0.00538 | 0.00336 | 0.00739 |

7.6.4 Day 29 Pseudo virus-neutralizing antibody (80% titer)




Figure 7.24: Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals.

Table 7.24: Table of risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.183 | $1.52 * 10^1$ | 0.00750 | 0.00279 | 0.01221 |
| 1.300 | $2.00 * 10^1$ | 0.00567 | 0.00238 | 0.00897 |
| 1.385 | $2.43 * 10^1$ | 0.00669 | 0.00337 | 0.01001 |
| 1.477 | $3.00 * 10^1$ | 0.00728 | 0.00407 | 0.01050 |
| 1.541 | $3.48 * 10^1$ | 0.00783 | 0.00469 | 0.01097 |
| 1.632 | $4.29 * 10^1$ | 0.00694 | 0.00434 | 0.00955 |
| 1.707 | $5.09 * 10^1$ | 0.00659 | 0.00414 | 0.00904 |
| 1.839 | $6.90 * 10^1$ | 0.00632 | 0.00408 | 0.00856 |
| 1.956 | $9.04 * 10^1$ | 0.00605 | 0.00392 | 0.00817 |
| 2.719 | $5.24 * 10^2$ | 0.00538 | 0.00349 | 0.00727 |

7.7 Plots and Tables with estimates and pointwise confidence interval for Day 57 (monotone-corrected)

MOCK

7.7.1 Day 57 Spike protein binding antibody




Figure 7.25: Adjusted threshold-response function for a range of thresholds of the Day 57 Spike protein binding antibody levels with simultaneous 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.25: Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Spike protein binding antibody levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 2.450 | $2.82 * 10^2$ | 0.01511 | 0.00000 | 0.03043 |
| 2.815 | $6.53 * 10^2$ | 0.01511 | 0.00000 | 0.03427 |
| 3.033 | $1.08 * 10^3$ | 0.01511 | 0.00429 | 0.02593 |
| 3.221 | $1.66 * 10^3$ | 0.01386 | 0.00423 | 0.02350 |
| 3.394 | $2.48 * 10^3$ | 0.01158 | 0.00333 | 0.01983 |
| 3.603 | $4.01 * 10^3$ | 0.01097 | 0.00394 | 0.01801 |
| 3.716 | $5.20 * 10^3$ | 0.00948 | 0.00417 | 0.01479 |
| 3.841 | $6.93 * 10^3$ | 0.00854 | 0.00416 | 0.01293 |
| 3.973 | $9.40 * 10^3$ | 0.00774 | 0.00402 | 0.01146 |
| 4.007 | $1.02 * 10^4$ | 0.00468 | 0.00281 | 0.00654 |

7.7.2 Day 57 RBD binding antibody




Figure 7.26: Adjusted threshold-response function for a range of thresholds of the Day 57 RBD binding antibody levels with simultaneous 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.26: Table of monotone-corrected risk estimates for a range of thresholds of Day 57 RBD binding antibody levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 2.478 | $3.01 * 10^2$ | 0.01500 | 0.00297 | 0.02704 |
| 2.882 | $7.62 * 10^2$ | 0.01500 | 0.00353 | 0.02647 |
| 3.132 | $1.36 * 10^3$ | 0.01221 | 0.00397 | 0.02045 |
| 3.338 | $2.18 * 10^3$ | 0.01174 | 0.00436 | 0.01913 |
| 3.514 | $3.27 * 10^3$ | 0.00996 | 0.00397 | 0.01595 |
| 3.722 | $5.27 * 10^3$ | 0.00776 | 0.00342 | 0.01210 |
| 3.866 | $7.35 * 10^3$ | 0.00622 | 0.00280 | 0.00964 |
| 3.986 | $9.68 * 10^3$ | 0.00569 | 0.00276 | 0.00862 |
| 4.125 | $1.33 * 10^4$ | 0.00546 | 0.00288 | 0.00805 |
| 4.211 | $1.63 * 10^4$ | 0.00468 | 0.00284 | 0.00652 |

7.7.3 Day 57 Pseudo virus-neutralizing antibody (50% titer)




Figure 7.27: Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.27: Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.765 | $5.82 * 10^1$ | 0.01328 | 0.00000 | 0.02821 |
| 2.143 | $1.39 * 10^2$ | 0.01259 | 0.00151 | 0.02368 |
| 2.345 | $2.21 * 10^2$ | 0.00760 | 0.00219 | 0.01301 |
| 2.519 | $3.30 * 10^2$ | 0.00730 | 0.00340 | 0.01120 |
| 2.657 | $4.54 * 10^2$ | 0.00730 | 0.00302 | 0.01159 |
| 2.867 | $7.36 * 10^2$ | 0.00656 | 0.00353 | 0.00959 |
| 3.005 | $1.01 * 10^3$ | 0.00611 | 0.00344 | 0.00878 |
| 3.174 | $1.49 * 10^3$ | 0.00552 | 0.00323 | 0.00781 |
| 3.387 | $2.44 * 10^3$ | 0.00525 | 0.00320 | 0.00731 |
| 4.038 | $1.09 * 10^4$ | 0.00468 | 0.00284 | 0.00651 |

7.7.4 Day 57 Pseudo virus-neutralizing antibody (80% titer)




Figure 7.28: Adjusted threshold-response function for a range of thresholds of the Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.28: Table of monotone-corrected risk estimates for a range of thresholds of Day 57 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.954 | $8.99 * 10^1$ | 0.00807 | 0.00007 | 0.01608 |
| 2.309 | $2.04 * 10^2$ | 0.00807 | 0.00038 | 0.01577 |
| 2.516 | $3.28 * 10^2$ | 0.00807 | 0.00279 | 0.01336 |
| 2.644 | $4.41 * 10^2$ | 0.00685 | 0.00334 | 0.01035 |
| 2.764 | $5.81 * 10^2$ | 0.00673 | 0.00314 | 0.01032 |
| 2.909 | $8.11 * 10^2$ | 0.00635 | 0.00353 | 0.00916 |
| 3.031 | $1.07 * 10^3$ | 0.00599 | 0.00347 | 0.00852 |
| 3.162 | $1.45 * 10^3$ | 0.00562 | 0.00333 | 0.00791 |
| 3.371 | $2.35 * 10^3$ | 0.00519 | 0.00314 | 0.00724 |
| 4.187 | $1.54 * 10^4$ | 0.00468 | 0.00284 | 0.00651 |

7.8 Plots and Tables with estimates and pointwise confidence intervals for Day 29 (monotone-corrected)

MOCK

7.8.1 Day 29 Spike protein antibody




Figure 7.29: Adjusted threshold-response function for a range of thresholds of the Day 29 Spike protein antibody levels with simultaneous 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.29: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Spike protein antibody levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.532 | $3.40 * 10^1$ | 0.02025 | 0.00000 | 0.05329 |
| 1.886 | $7.69 * 10^1$ | 0.02025 | 0.00000 | 0.04141 |
| 2.138 | $1.37 * 10^2$ | 0.01159 | 0.00219 | 0.02099 |
| 2.351 | $2.24 * 10^2$ | 0.01002 | 0.00304 | 0.01699 |
| 2.522 | $3.33 * 10^2$ | 0.00899 | 0.00433 | 0.01364 |
| 2.733 | $5.41 * 10^2$ | 0.00684 | 0.00352 | 0.01016 |
| 2.903 | $8.00 * 10^2$ | 0.00656 | 0.00374 | 0.00938 |
| 3.112 | $1.29 * 10^3$ | 0.00638 | 0.00373 | 0.00903 |
| 3.348 | $2.23 * 10^3$ | 0.00609 | 0.00379 | 0.00839 |
| 4.007 | $1.02 * 10^4$ | 0.00538 | 0.00336 | 0.00739 |

7.8.2 Day 29 RBD binding antibody




Figure 7.30: Adjusted threshold-response function for a range of thresholds of the Day 29 RBD binding antibody levels with simultaneous 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.30: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 RBD binding antibody levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 1.620 | $4.17 * 10^1$ | 0.02409 | 0.00000 | 0.06609 |
| 2.052 | $1.13 * 10^2$ | 0.01767 | 0.00051 | 0.03483 |
| 2.345 | $2.21 * 10^2$ | 0.01117 | 0.00343 | 0.01890 |
| 2.575 | $3.76 * 10^2$ | 0.01000 | 0.00363 | 0.01636 |
| 2.780 | $6.03 * 10^2$ | 0.00851 | 0.00392 | 0.01310 |
| 3.010 | $1.02 * 10^3$ | 0.00693 | 0.00370 | 0.01017 |
| 3.217 | $1.65 * 10^3$ | 0.00609 | 0.00347 | 0.00871 |
| 3.461 | $2.89 * 10^3$ | 0.00609 | 0.00362 | 0.00857 |
| 3.736 | $5.45 * 10^3$ | 0.00544 | 0.00331 | 0.00758 |
| 4.211 | $1.63 * 10^4$ | 0.00538 | 0.00336 | 0.00740 |

7.8.3 Day 29 Pseudo virus-neutralizing antibody (50% titer)




Figure 7.31: Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.31: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (50% titer) levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|---------------|---------------|---------|----------|
| 0.548 | $3.53 * 10^0$ | 0.05182 | 0.02597 | 0.07766 |
| 0.873 | $7.46 * 10^0$ | 0.01181 | 0.00112 | 0.02249 |
| 1.032 | $1.08 * 10^1$ | 0.00819 | 0.00296 | 0.01341 |
| 1.147 | $1.40 * 10^1$ | 0.00721 | 0.00314 | 0.01128 |
| 1.271 | $1.87 * 10^1$ | 0.00721 | 0.00370 | 0.01072 |
| 1.427 | $2.67 * 10^1$ | 0.00721 | 0.00383 | 0.01059 |
| 1.526 | $3.36 * 10^1$ | 0.00653 | 0.00367 | 0.00939 |
| 1.656 | $4.53 * 10^1$ | 0.00594 | 0.00353 | 0.00835 |
| 1.852 | $7.11 * 10^1$ | 0.00550 | 0.00337 | 0.00763 |
| 2.879 | $7.57 * 10^2$ | 0.00538 | 0.00336 | 0.00739 |

7.8.4 Day 29 Pseudo virus-neutralizing antibody (80% titer)




Figure 7.32: Adjusted threshold-response function for a range of thresholds of the Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals. The estimates and confidence intervals are adjusted using the assumption that the true threshold-response is nonincreasing.

Table 7.32: Table of monotone-corrected risk estimates for a range of thresholds of Day 29 Pseudo virus-neutralizing antibody (80% titer) levels with simultaneous 95% confidence intervals.

| \log_{10} -Threshold | Threshold | Risk estimate | CI left | CI right |
|------------------------|--------------------|---------------|---------|----------|
| 1.183 | 1.52×10^1 | 0.00750 | 0.00279 | 0.01221 |
| 1.300 | 2.00×10^1 | 0.00699 | 0.00369 | 0.01028 |
| 1.385 | 2.43×10^1 | 0.00699 | 0.00367 | 0.01031 |
| 1.477 | 3.00×10^1 | 0.00699 | 0.00377 | 0.01020 |
| 1.541 | 3.48×10^1 | 0.00699 | 0.00385 | 0.01013 |
| 1.632 | 4.29×10^1 | 0.00694 | 0.00434 | 0.00955 |
| 1.707 | 5.09×10^1 | 0.00659 | 0.00414 | 0.00904 |
| 1.839 | 6.90×10^1 | 0.00632 | 0.00408 | 0.00856 |
| 1.956 | 9.04×10^1 | 0.00605 | 0.00392 | 0.00817 |
| 2.719 | 5.24×10^2 | 0.00538 | 0.00349 | 0.00727 |

Chapter 8

Day 57 Univariate CoR: Nonlinear modeling

To explore nonlinear association and threshold modeling, we fit smoothing spline models using the mgcv R package and two-phase models using the chngpt R package.




Figure 8.1: Marginalized risk as functions of Day 57 markers ($=s$) among baseline seronegative vaccine recipients with 95% bootstrap point-wise confidence bands (5 replicates) as modeled by GAM with automatic smoothness estimation. The horizontal lines indicate the overall cumulative risk of the vaccine and placebo arms by Day 164 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. $\text{lod} = 0.3, 1.6, 2.4, 15$ for bAb Spike, bAb RBD, PsV nAb ID50, PsV nAb ID80, respectively.




Figure 8.2: Marginalized risk as functions of Day 57 markers (=s) among baseline seronegative vaccine recipients with 95% bootstrap point-wise confidence bands (5 replicates) as modeled by GAM with automatic smoothness estimation. The horizontal lines indicate the overall cumulative risk of the vaccine arm by Day 164 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3, 1.6, 2.4, 15 for bAb Spike, bAb RBD, PsV nAb ID50, PsV nAb ID80, respectively.

MOCK

Chapter 9

Day 29 Univariate CoR: Nonlinear modeling

To explore nonlinear association and threshold modeling, we fit smoothing spline models using the mgcv R package and two-phase models using the chngpt R package.




Figure 9.1: Marginalized risk as functions of Day 29 markers ($=s$) among baseline seronegative vaccine recipients with 95% bootstrap point-wise confidence bands (5 replicates) as modeled by GAM with automatic smoothness estimation. The horizontal lines indicate the overall cumulative risk of the vaccine and placebo arms by Day 192 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. $\text{lod} = 0.3, 1.6, 2.4, 15$ for bAb Spike, bAb RBD, PsV nAb ID50, PsV nAb ID80, respectively.




Figure 9.2: Marginalized risk as functions of Day 29 markers (=s) among baseline seronegative vaccine recipients with 95% bootstrap point-wise confidence bands (5 replicates) as modeled by GAM with automatic smoothness estimation. The horizontal lines indicate the overall cumulative risk of the vaccine arm by Day 192 and its 95% point-wise confidence interval. Histograms of the immunological markers in the vaccine arm are overlaid. lod = 0.3, 1.6, 2.4, 15 for bAb Spike, bAb RBD, PsV nAb ID50, PsV nAb ID80, respectively.

MOCK

Chapter 10

Appendix

- This report was built from the [CoVPN/correlates_reporting](#) repository with commit hash 27e2aeb35dc06e21c682cc3bd143ef4e791e231b. A diff of the changes introduced by that commit may be viewed at https://github.com/CoVPN/correlates_reporting/commit/27e2aeb35dc06e21c682cc3bd143ef4e791e231b
- The sha256 hash sum of the raw input file, “COVID_VEtiral_practicedata_primarystage1.csv”: 83d0f55d1745ffd42be124d8f9ec9a9903abcc13cd22f95e537542a08b41300a
- The sha256 hash sum of the processed file, “moderna_mock_data_processed.csv”: 28964ce20cfcd70a621aff9df412c42b11